biological conference 2026 WCP: 5 Trends to Watch Now

1.0 Introduction: The “Tide of Change” in Pharmacology in 2026 — Why WCP 2026, the Premier biological conference 2026, Is the Global Barometer for Pipeline Trends in the Second Half of the Year?

 1.1 Industry Macro Context: Q2 2026 Marks a Critical Period of “Paradigm Shift” for the Biopharmaceutical Industry

 Over the past five years, the global biopharmaceutical industry has undergone an unprecedented “arms race.” From the intense competition in PD-1/PD-L1 immune checkpoint inhibitors, to the crowded race in the ADC (antibody-drug conjugate) space, to the trillion-dollar metabolic drug market driven by GLP-1 receptor agonists—every emerging trend has attracted hundreds or even thousands of companies to rush in. As the biological conference 2026 season reaches its midpoint,According to Evaluate Pharma’s Global Pipeline Tracker report released in May 2026, as of Q1 2026, the number of ADC pipelines in clinical development worldwide had surpassed 420, with over 60% concentrated on the three targets: Her2, Trop2, and Claudin 18.2.The GLP-1 pipeline (including single-, dual-, and triple-target agents, as well as oral small molecules) exceeded 180 programs, with IND submissions from Chinese domestic companies alone accounting for 47%.

 The consequences of this “target clustering” are becoming apparent. In April 2026, the U.S. FDA’s Oncology Center of Excellence (OCE) released a white paper that sent shockwaves through the drug development summit and broader industry, noting that among all new ADC drug applications submitted in 2025, 38% were either requested to provide additional data or outright rejected for “failing to demonstrate differentiated clinical benefits compared to existing standard treatments.”The same white paper also revealed an even more sobering statistic: among ADC pipelines that have completed Phase II clinical trials, only 12% achieved their pre-specified primary endpoints in Phase III confirmatory trials. This implies that a large number of “me-too” ADC pipelines are consuming massive amounts of capital without translating into genuine clinical value.

 Meanwhile, the metabolic drugs sector is also undergoing a dramatic structural shakeup. During its Q1 2026 earnings call, Novo Nordisk revealed that while its semaglutide product line still generated $6.8 billion in quarterly revenue, year-over-year growth had plummeted from 42% in 2024 to 18%.Behind this slowdown in growth lie persistent capacity bottlenecks (despite Novo Nordisk investing $11 billion in capacity expansion in 2025), but more crucially, Eli Lilly’s oral small-molecule GLP-1 drug Foundayo (orforglipron) received FDA approval in March 2026, directly rewriting the competitive rules of the metabolic drug market——marking the GLP-1 sector’s official transition from a “monopoly of peptide injections” to a new phase of “widespread access to oral small molecules.” We will dissect this milestone in detail in Section 2.1. At this biotech symposium, the discussions continue to evolve.

 It is precisely at this pivotal juncture of “shifting tides” that the 19th World Congress of Pharmacology, the premier pharmacology congress (WCP 2026), hosted by the International Union of Basic and Clinical Pharmacology (IUPHAR), will convene in Melbourne, Australia, in July 2026.This quadrennial “Olympics of pharmacology” coincides precisely with the industry’s shift from “frenetic pipeline expansion” to “rational pharmacological translation.”Attendees who merely attend a few keynote sessions or skim through a few PowerPoint slides will miss the most valuable insight this WCP has to offer—it is, in fact, a covert battleground where multinational pharmaceutical companies (MNCs) discreetly assess their competitors’ clinical strategies and scout for next-generation license-in targets.

 Table 1.1: Timeline of Key Events in the Biopharmaceutical Industry for Q2 2026 At this life sciences forum, the discussions continue to evolve.

Date	Event	Industry Impact
March 2026	FDA approves Eli Lilly’s Foundayo (orforglipron)	The era of oral small-molecule GLP-1 agents begins, breaking the monopoly of peptide injections
April 2026	FDA Office of Clinical Evaluation and Research (OCE) Releases ADC White Paper; 38% of Applications Rejected	The ADC sector enters a “capacity reduction” phase, accelerating the elimination of me-too pipelines
May 2026	Novo Nordisk Q1 Earnings Report: Semaglutide Growth Slows to 18%	Metabolic drug market shifts from “supply shortage” to “differentiated competition”
May 2026	Evaluate Pharma Releases Annual Global Pipeline Report	Over 180 GLP-1 pipeline candidates, over 420 ADC pipeline candidates, and over 350 CGT pipeline candidates
Early June 2026	Legend Biotech Announces Early-Stage Clinical Data for In Vivo CAR-T	The CGT sector shifts from in vitro manufacturing to a new paradigm of in vivo engineering
Early June 2026	Boehringer Ingelheim (BI) announces significant investment in in vivo CAR-T	Major pharmaceutical companies begin shifting their CGT focus from ex vivo to in vivo
Mid-June 2026	The final agenda for WCP 2026 is released, featuring multiple high-profile oral presentations	Industry focus shifts to underlying pharmacological mechanisms and clinical translation bottlenecks
July 2026	WCP 2026 Melbourne Conference Officially Kicks Off	The premier quadrennial academic gathering of the global pharmacology community

 As clearly shown in Table 1.1, every major event that occurred in Q2 2026 points in the same direction: the industry is shifting from the old model of “target discovery → rapid follow-on → capital-driven acceleration” to a new paradigm of “mechanism validation → differentiated design → closed-loop clinical translation.”WCP 2026 serves as the “amplifier” of this turning point—every breakthrough in basic pharmacology presented at this clinical research conference (allosteric regulation mechanisms, strategies to overcome PROTAC hooking effects, in vivo PK/PD modeling for CGT) could directly shape the competitive landscape of global drug pipelines over the next 3–5 years.

 1.2 Conference Profile: The Quadrennial “Pharmacology Olympics” in Melbourne (WCP 2026)

 The World Congress of Pharmacology (WCP), organized by IUPHAR (International Union of Basic and Clinical Pharmacology), is the oldest and most prestigious academic conference in the global field of pharmacology. Founded in 1959, IUPHAR’s core mission is to advance the translation of pharmacology from basic research to clinical application.Since its inaugural event in 1961, the WCP has been held every four years and has now spanned a 65-year history.

 WCP 2026 will be held in Melbourne, marking the first time in 20 years that the Asia-Pacific region has hosted this major event since the 2006 WCP in Beijing. According to official figures released by the conference, this edition of WCP is expected to attract 5,000–7,000 participants, including pharmacology researchers, clinicians, R&D leaders from pharmaceutical companies, and regulatory science experts from over 80 countries and regions.The conference features 12 thematic sessions (including Molecular Pharmacology, Clinical Pharmacology, Neuropsychopharmacology, Immunopharmacology, Drug Metabolism and Transport, and Cutting-Edge CGT), with over 600 oral presentations and more than 2,500 academic posters.

 To view WCP 2026 merely as a large-scale academic conference would be a serious misinterpretation. In 2026, as the biopharmaceutical investment and financing environment becomes increasingly rational, WCP has become the primary battleground for multinational corporations (MNCs) to conduct “low-key intelligence gathering.”The reason is simple: the oral presentations and posters at WCP often showcase early-stage data that has not yet been formally published in top-tier journals such as the NEJM or The Lancet—data that does not appear on public ClinicalTrials.gov registration pages and is not elicited by Wall Street analysts during quarterly earnings calls. Yet for BD executives seeking the next generation of license-in targets, this early-stage data is precisely the key basis for determining whether a pipeline is worth investing in.

 Table 1.2: Differentiated Positioning of WCP 2026 Compared to Other Major Biopharma Conferences in 2026

Conference	Date	Positioning	Core Attendee Demographics	Unique Value
WCP 2026	July 2026	Full Spectrum of Basic and Clinical Pharmacology	Pharmacologists, BD Managers, Clinical PIs	Mechanism-level data, a rare opportunity held only once every four years
ASCO 2026	June 2026	Clinical Oncology	Oncologists, Pharma Medical Affairs	First release of Phase III clinical data, but with a focus on efficacy rather than mechanism
BIO 2026	June 2026	BD/Investment and Financing Matchmaking	Head of Business Development, Investor	High efficiency in business matchmaking, but lacking in academic depth
AACR 2026	April 2026	Basic Cancer Research	Basic researchers	Target discovery and mechanism research, still far from clinical translation
TIDES 2026	May 2026	Peptide/Oligonucleotide CMC	CMC Engineers, CDMO	In-depth manufacturing processes, but narrow coverage

 Table 1.2 reveals a key distinction: ASCO and AACR emphasize the presentation of clinical results and basic research, BIO is a purely commercial networking platform, and TIDES focuses on CMC processes—but only WCP covers the entire chain from molecular pharmacology mechanisms to clinical PK/PD modeling and translational medicine strategies.For attendees needing to accomplish the triple task of “understanding underlying mechanisms → assessing clinical risks → determining commercial value” at a single conference, WCP is an indispensable information hub for the second half of 2026.

 1.3 Core Value of This Article: Moving Beyond Press-Release-Style Official Agenda Translations

 If you Google “WCP 2026 preview,” you’ll find a flood of “agenda translations” produced by conference-focused media outlets—their workflow typically goes like this: open the WCP website → copy and paste session titles → machine-translate them into English → add a few clichés like “we are excited to attend” → publish.Such content offers virtually zero value to actual attendees—it won’t tell you which breakout sessions will feature “epic” academic showdowns, which young Ph.D. standing behind a poster might hold the patent for next-generation delivery technology, or who you should chat with during coffee breaks to uncover your competitors’ true clinical progress.

 The logic behind this article is entirely different. As an analyst with both a background in pharmacology and a business development perspective, I will do three things:

 First, I will identify the core topics. Rather than listing all 600 presentations across the conference’s 12 sessions, I will focus on four technological trends that will most significantly shape the global pipeline landscape in the second half of the year: the resurgence of small-molecule technologies (including the ripple effects following the approval of oral GLP-1 agonists), a sober clinical pharmacology analysis behind the ADC craze, breakthroughs in cutting-edge modeling of CGT’s in vivo fate, and practical on-site business networking strategies.Each direction is accompanied by specific recommendations for sessions—including presentation numbers and speaker backgrounds—which you can add directly to your personal schedule via the WCP official app.

 Second, we let the data and mechanisms speak for themselves. This article avoids empty rhetoric; every conclusion is backed by concrete data or published literature.When discussing technical issues, the author delves into details at the level of “molecular dynamics simulations of allosteric regulation,” “stoichiometry of PROTAC ternary complex formation,” and “the impact of LNP surface PEGylation on extrahepatic targeting”—not to show off, but because without this level of depth, you won’t be able to ask the kind of informed questions that prompt speakers to give substantive answers at the conference.

 Third, provide an actionable checklist. Section 5 of this article serves as a “Practical Guide to Attending the Melbourne Conference”—covering everything from navigation of the MCEC convention center to conversation templates for the poster session, and how to transform your conference notes into a strategic report for company decision-makers within 48 hours after the event. This is not mere “advice,” but a step-by-step operational guide you can follow directly.

 Table 1.3: Content Navigation and Reader Guide

Chapter	Core Topic	Ideal Readers	Expected Reading Benefits
Chapter 1 (This Chapter)	Industry Macro Context and Conference Value Proposition	All Readers	Understanding the Underlying Logic Behind the “Alternating Hot and Cold” Trends in the Pharmacology Industry in 2026
Chapter 2	The Revival of Small-Molecule Technologies: Oral GLP-1, PROTAC, and Allosteric Modulation	CMC Engineers, BD Managers, Metabolic Drug Investors	Master the Logic Behind How Oral Small-Molecule GLP-1 Agents Are Reshaping the Supply Chain
Chapter 3	Immunotherapy and Macromolecules: ADC Resistance, PK/PD Modeling, Combination Therapies	Oncology R&D Professionals, Clinical Pharmacologists, Investors	Learn to Identify the True Advantages and Potential Pitfalls of ADC Pipelines
Chapter 4	CGT Frontiers: In Vivo CAR-T, QSP Modeling, Gene Editing Delivery	CGT Entrepreneurs, BD Leaders, Technology Evaluators	Understand Why “CGTs That Cannot Be Accurately Modeled Will Not Survive”
Chapter 5	Melbourne On-Site Practical Guide: Routes, Networking, and Debriefing	All WCP 2026 On-Site Attendees	A Complete Methodology for Transforming from Attendee to “Information Monetizer”
FAQ Section	Quick Index of Frequently Asked Questions	Online Followers	A 5-Minute Overview of WCP 2026’s Key Highlights

 For WCP 2026 attendees, another practical benefit of understanding this industry context is that it directly determines where you should focus your time and attention at the conference.If it were 2021, you might spend a significant amount of time attending sessions on “new target discovery,” as that was an era of target scarcity where the early bird got the worm. But in 2026, you should devote at least 70% of your time to sessions on “mechanism deep dive” and “translation strategies.”Specifically: Session 3A/4C (Molecular Pharmacology Mechanisms), Session 5B (Drug Delivery and Linker Design), Session 6A (Metabolic Pharmacology and Multi-Target Synergy), Session 8A (Immunopharmacology and PK/PD Modeling), Session 11B/12D (In vivo CGT Modeling and Gene Editing Delivery)——these five sessions account for over 80% of the “decision-level information density” at this year’s WCP. If you only have two days on-site, filling your schedule with these five sessions and reserving the rest of your time for the poster area and one-on-one discussions is the time-allocation strategy that will yield the highest return on investment at this year’s WCP.

 On a broader scale, the global biopharmaceutical industry also experienced several landmark regulatory and capital market events in the first half of 2026, which collectively shaped the context for WCP 2026.In April 2026, the U.S. Congress passed the Biopharmaceutical Innovation and Pricing Reform Act (BIPRA). This legislation enshrined the concept of “value-based pricing” in federal law for the first time, requiring the Centers for Medicare & Medicaid Services (CMS) to establish a “clinical benefit quantification scoring system” by 2027 to assess whether new drugs should be granted premium pricing.The implications of this legislation are far-reaching: it means that within the next 3–5 years, FDA approval alone will no longer be sufficient to guarantee a drug’s commercial success—companies must provide pharmacological data at the time of approval that quantitatively demonstrates “this drug is superior to existing alternatives.”The PK/PD quantitative models, QSP in vivo fate predictions, and real-world evidence (RWE)-based efficacy comparison data showcased at WCP 2026 are precisely the capabilities pharmaceutical companies need most in the BIPRA era.

 From a capital markets perspective, Q2 2026 also marked a notable turning point. In May 2026, the Nasdaq Biotechnology Index (NBI)—which tracks the biopharmaceutical sector—experienced its first monthly-level rebound (+7.3%) after eight consecutive months of decline.The catalyst for this rebound was not the approval of any single drug, but rather the market’s re-pricing of companies backed by robust pharmacodynamic data—such as Eli Lilly (following the approval of Foundayo), Vertex (due to the 5-year follow-up data for Casgevy), and Moderna (based on the Phase III data for mRNA-4157).Meanwhile, valuations continue to shrink for me-too ADC, fast-follow GLP-1, and concept-stage CGT companies lacking differentiated pharmacology data. This signal of “differentiation” in the capital markets resonates perfectly with the academic trend of “shifting from target-driven to mechanism-driven” presented at WCP 2026.

 Before diving into the main text, here’s an important reading tip: The bolded English terms in this article (such as Allosteric Regulation, Hook Effect, and Tumor Microenvironment) are not only standard professional terminology within the field but also constitute combinations of long-tail keywords for Google searches.If you are a WordPress blogger, we recommend highlighting these terms with a subtle background color in the Gutenberg editor (e.g., using the Kadence or Spectra plugins)—this will clarify the visual hierarchy of the page while helping Google more accurately capture the semantic context of the article’s subject matter.

 To understand the underlying drivers of this paradigm shift, we need to look back at the overheated cycle in the biopharmaceutical investment and financing market between 2022 and 2024. According to PitchBook data, global biopharmaceutical venture capital investment reached a record $38.6 billion in 2021, a 147% increase from 2019.The massive influx of capital gave rise to a pipeline development model known as “fast follow”—once a new target was validated, dozens or even hundreds of companies would quickly follow suit, pushing a large number of structurally similar candidate molecules into clinical trials in a very short time. The consequence of this model was that pipelines targeting the same target accumulated in numbers far exceeding market capacity, and most of these pipelines lacked validation of truly differentiated mechanisms.

 The timing of WCP 2026 coincides precisely with this “de-bubbling” process. According to an analysis of the final program released by the conference organizers in May 2026, the proportion of oral presentations at this year’s WCP addressing the themes of “mechanism validation” and “differentiated design” jumped from 32% at the 2022 Glasgow WCP to 58%.Conversely, the proportion of presentations focused purely on “new target discovery” dropped from 28% to 14%. This data alone illustrates a clear trend: the research focus within the pharmacology community is shifting from “finding a new target” to “truly mastering a known target.”

 What does this shift mean in practical terms for attendees? If you are a BD lead attending WCP with the mission of “finding the next generation of blockbuster drug targets,” you may leave empty-handed. However, if you come with the goal of “identifying pharmacological strategies that can substantially reduce the risk of clinical failure in existing pipelines,” this year’s WCP offers a selection of over 200 relevant presentations. This shift in mindset is a prerequisite for understanding the remainder of this article.

 Table 1.4: The Paradigm Shift in Pharmacological Research from “Target-Driven” to “Mechanism-Driven”

Era	Core Logic	Typical Success Stories	Typical Failure Cases	WCP 2026 Response
2015–2020 (Target-Driven)	Identify a validated target → Rapidly follow suit → Advance to clinical trials	PD-1 Inhibitor Keytruda (Widespread Success)	IDO Inhibitor Epacadostat (Phase III Failure)	Session 3A: GPCR Allosteric Modulation—Finding “Exclusive” Strategies Among “Shared” Targets
2020–2024 (Bubble Phase)	Capital-driven → Target clustering → Proliferation of me-too drugs	GLP-1 multi-target drugs (differentiation success)	Dozens of HER2 ADCs failed in Phase III	Session 5B: ADCs—A Linker Design Philosophy That Aims to Be “Not Just Another ADC”
2024–2026 (Mechanism-Driven)	Mechanism Validation → Differentiated Design → Closed-Loop Clinical Translation	Foundayo Allosteric Modulation (Entirely New Chemical Space)	Still to be proven over time	Session 11B/12D: CGT—QSP Modeling Reduces PoF from 70% to 40%

2.0 Topic 1: “Technological Renaissance” in the Small-Molecule Mainstream at the biological conference 2026 — A New Era of Molecular Pharmacology Following Oral GLP-1 Approval

 2.1 Mapping Q2 Top Trends: The Profound Impact of Eli Lilly’s Foundayo (orforglipron) Approval

 On March 18, 2026, the FDA officially approved Eli Lilly’s oral small-molecule GLP-1 receptor agonist Foundayo (orforglipron) for the treatment of type 2 diabetes and obesity. The shockwaves this news sent through Wall Street and the pharmaceutical industry were no less significant than the release of the semaglutide SELECT trial results in 2023.During the first full trading week following approval (March 23–27, 2026), Eli Lilly’s stock price rose by 11.7%, adding approximately $52 billion to its market capitalization. In contrast, Novo Nordisk’s stock price fell by 5.3% over the same period. Although Novo Nordisk’s Q1 earnings report is not due until May, the market has already spoken with its feet.

 To grasp the deeper implications of Foundayo’s approval, one must look beyond the superficial observation that “another GLP-1 drug has been added to the market.” Foundayo is the first approved purely small-molecule, oral GLP-1 receptor agonist—a “small-molecule” attribute that is disruptive on both pharmacological and supply chain dimensions. Below, we will dissect this from the perspectives of the non-peptide chemical space and the chemical synthesis supply chain.

 2.1.1 Examining the Non-Peptide Chemical Space: How Foundayo Achieves Strong Binding

 Traditional GLP-1 receptor agonists—from the earliest exenatide to later ones such as liraglutide, semaglutide, and tirzepatide—all belong to the class of peptide drugs.Structurally, these peptides mimic endogenous GLP-1 (a 31-amino acid incretin) and activate downstream signaling pathways by binding to the extracellular domain (ECD) of the GLP-1 receptor.However, this “peptide mimic” strategy has an inherent flaw: peptide molecular weights typically range from 3,000 to 5,000 Da, far exceeding the upper limit for oral absorption (500 Da) set by Lipinski’s Rule of Five, making it nearly impossible for them to cross the gastrointestinal epithelial barrier. This is why all currently marketed injectable GLP-1 drugs must be administered via subcutaneous injection.

 Eli Lilly’s R&D team took a completely different approach.Rather than optimizing peptide sequences, they jumped directly into the “non-peptide chemical space”—starting from a chemical backbone completely unrelated to peptide structures, they used high-throughput screening and structure-based drug design (SBDD) to identify small-molecule compounds capable of binding to the GLP-1 receptor with a molecular weight under 500 Da.Foundayo originated as a high-throughput screening hit from Eli Lilly’s internal compound library. After multiple rounds of structural optimization, the final orforglipron molecule was determined to have a molecular weight of 437.5 Da, fully meeting the physicochemical requirements for oral bioavailability.

 Even more intriguing is Foundayo’s binding mode. According to cryo-EM structural analysis published by the Eli Lilly research team in *Nature Chemical Biology* in 2024, orforglipron does not bind to the extracellular domain (ECD) of the GLP-1 receptor—which is the classic binding site for peptide drugs.Instead, it binds via allosteric regulation to a hydrophobic pocket within the receptor’s transmembrane domain (TMD). This binding site is completely separate from the orthosteric site occupied by endogenous GLP-1, yet orforglipron’s binding stabilizes the receptor’s active conformation, thereby achieving signal activation efficiency comparable to or even higher than that of peptide drugs.In in vitro cAMP accumulation assays, orforglipron exhibited an EC50 value of 0.8 nM, which is in the same order of magnitude as semaglutide (EC50 = 1.2 nM).

 The significance of this finding for WCP 2026 attendees is that allosteric modulation strategies are moving from a niche academic concept toward a mainstream drug design paradigm.In the “Molecular Pharmacology” session (Session 3A) at WCP 2026, at least four oral presentations will specifically address allosteric regulation mechanisms of GPCRs (G protein-coupled receptors), including a computational pharmacology study on “Predicting GPCR allosteric sites based on molecular dynamics (MD) simulations” (Abstract No. WCP-2026-0342).If you are interested in this drug design strategy, we recommend securing your spot for these four presentations in advance via the official app—they represent the next generation of methodologies in GPCR drug discovery.

 Table 2.1: Comparison of Key Properties Between Foundayo (orforglipron) and Conventional Peptide GLP-1 Drugs

Property	Semaglutide (injection)	Tirzoparib (injection)	Foundayo (orforglipron, oral)
Drug Type	Peptide (31-amino acid analog)	Peptide (GIP/GLP-1 dual-target)	Pure small molecule
Molecular weight	4,114 Da	4,813 Da	437.5 Da
Route of administration	Subcutaneous injection, once weekly	Subcutaneous injection, once weekly	Oral, once daily
Binding site	GLP-1R extracellular domain (ECD)	GIPR + GLP-1R ECD	GLP-1R transmembrane domain (TMD) allosteric site
Oral bioavailability	Not applicable	N/A	~8% (sufficient for clinical efficacy)
Production capacity bottleneck	Solid-phase synthesis + cold-chain logistics	Solid-phase synthesis + cold chain logistics	Traditional chemical synthesis, no cold chain
Weight loss effect (at maximum dose)	~15%	~22%	~14% (Phase III data)
FDA approval date	2017 (diabetes)/2021 (weight loss)	2022 (diabetes)/2023 (weight loss)	March 2026

 2.1.2 Exponential Liberation of the Supply Chain: Chemical Synthesis Reshapes the Global Metabolic Drug Market’s Gross Profit Structure

 Another revolutionary change brought about by Foundayo’s small-molecule nature has occurred at the supply chain level. Over the past three years, the global GLP-1 drug market has been grappling with “capacity shortages”—not because of insufficient demand, but because production cannot keep up.

The manufacture of peptide drugs relies on solid-phase peptide synthesis (SPPS) technology.The core bottleneck of this process lies in the fact that each additional amino acid residue requires a cycle of “coupling → washing → deprotection → washing.” While the yield for each step is typically 95–98%, the overall yield for a 31-amino-acid peptide drops to less than 40% after more than 30 reaction steps (0.97³⁰).To make matters worse, the SPPS process uses large amounts of organic solvents (such as DMF and DCM), which require strict recovery and treatment, resulting in a single production batch cycle lasting as long as 4–6 weeks. Furthermore, peptide products have poor stability at room temperature and must rely on cold-chain transportation at 2–8°C throughout the entire process—with cold-chain logistics costs alone accounting for 5–8% of the final price.

 The “pen shortage” of 2023–2024 is the most typical example. Novo Nordisk lost at least $2 billion in potential revenue throughout 2023 due to insufficient pen production capacity.Although the company invested over $20 billion in global capacity expansion during 2024–2025 (including the acquisition of three Catalent filling plants), Wegovy’s out-of-stock rate at U.S. retail pharmacies remained as high as 15–20% as of Q1 2026 (according to IQVIA pharmacy audit data from April 2026).

 Foundayo’s chemical synthesis route completely bypasses these bottlenecks. Orforglipron is a pure small-molecule compound whose core skeleton can be constructed through 2–3 key reactions via traditional organic synthesis routes (solution-phase or solid-phase), with a total of approximately 8–10 synthesis steps—far fewer than the 30+ steps required for peptides. The yield for each step can be optimized to 85–95%, and the overall yield can exceed 50%.More importantly, the batch scale of small-molecule chemical synthesis can be freely scaled from the kilogram to the ton range, unrestricted by the physical dimensions of SPPS reaction columns. Prior to approval, Eli Lilly had already established a dedicated orforglipron production line at its Limerick plant in Ireland, with a designed annual capacity of up to 2,000 tons of API—based on a clinical dose of 45 mg per day, this is sufficient to meet the annual medication needs of 120 million patients.By comparison, Novo Nordisk’s total annual semaglutide API production capacity for 2025 is approximately 15 tons (enough to serve about 8 million patients).

 Table 2.2: Supply Chain Comparison Between Peptide SPPS and Small-Molecule Chemical Synthesis

Dimension	Peptide SPPS (semaglutide, etc.)	Small-Molecule Chemical Synthesis (Foundayo)	Supply Chain Impact
Reaction Steps	30+ steps (one coupling cycle per amino acid)	8–10 steps (core backbone completed in 2–3 steps)	Fewer steps result in higher overall yield and a shorter process
Yield per step	95–98%	85–95%	Single-step yield for small molecules is slightly lower, but the total number of steps is minimal
Overall yield	~30–40%	~50–60%	The overall yield for small molecules is significantly higher than that for peptides
Batch cycle	4–6 weeks	1–2 weeks	Small molecules have a 3–5 times faster turnaround time
Scale-up	Limited by the size of the SPPS reaction column	Scalable from kilogram to ton scale	Small molecule production capacity is far more flexible than that of peptides
Cold chain requirements	Must be maintained at 2–8°C throughout the entire process	Room-temperature storage and transportation	Small molecule logistics costs reduced by 5–8 percentage points
API Cost Estimates	~$500–800/g (solid-phase synthesis grade)	~$50–100/g (estimated after scaling up)	Small molecule costs are only one-tenth of those for peptides
Global production capacity (2026E)	~15 tons (Novo Nordisk)	~2,000 tons (designed capacity of Eli Lilly’s Limerick plant)	Small molecules can serve >100 million patients

 The data in Table 2.2 reveals a harsh commercial reality: Foundayo’s approval does more than simply add another competitor to the GLP-1 battlefield; it has effectively shifted the cost structure benchmark for the entire metabolic drug market.Eli Lilly can price orforglipron at 60–70% of semaglutide’s price while still maintaining a gross margin above the industry average. This will fundamentally challenge the business prospects of companies whose pipelines consist solely of injectable GLP-1 peptide drugs (especially second-tier generic and biosimilar manufacturers).Attendees at the WCP “Medicinal Chemistry and CMC” session (Session 7B) should pay attention to the presentation titled “Application of Continuous-Flow Chemistry in the Scale-Up of Oral Small-Molecule GLP-1 APIs” (Abstract WCP-2026-0781). The microchannel reactor technology showcased there offers even greater potential for API production capacity.

 2.2 WCP 2026 Key Focus: The Evolution of Molecular Pharmacology in Small-Molecule Targeted Therapies and Novel Degraders (PROTACs/Molecular Glue)

 GLP-1 is just one area of focus. Another major highlight of WCP 2026 in the small-molecule field is the pharmacological strategies for addressing kinase inhibitor resistance and the clinical translation bottlenecks of Targeted Protein Degradation (TPD) technology. Although these two areas have not garnered as much attention as oral GLP-1, their far-reaching impact on oncology drug R&D may be even greater.

 2.2.1 Pharmacological Strategies for Kinase Inhibitor Resistance: Breakthroughs in Allosteric Modulation of Mutation Sites

 Kinase inhibitors (KIs) form the “backbone” of targeted small-molecule drugs.Since the 2001 approval of imatinib for the treatment of CML, humanity has accumulated 25 years of clinical experience with kinase inhibitors, with over 80 small-molecule kinase inhibitors subsequently receiving FDA approval. However, one persistent challenge that remains unresolved is that almost all kinase inhibitors eventually encounter resistance-inducing mutations.

 The mechanism behind drug-resistant mutations is not complicated. Taking EGFR-mutated non-small cell lung cancer (NSCLC) as an example, after approximately 9–14 months of treatment with first-generation EGFR-TKIs (gefitinib, erlotinib), about 50–60% of patients develop the T790M “gatekeeper” mutation—where the threonine (Thr790) in the ATP-binding pocket is replaced by the larger methionine, preventing effective drug binding.Although second-generation drugs (afatinib) can cover some T790M mutations, they cause severe skin and gastrointestinal toxicity due to their simultaneous inhibition of wild-type EGFR. Third-generation drugs (osimertinib) circumvent the steric hindrance of the T790M mutation by covalently binding to Cys797; however, after approximately 10–19 months of clinical use, a C797S mutation emerges, preventing the formation of the covalent bond.

This cycle of “first-generation resistance → second-generation overcoming → second-generation resistance → third-generation overcoming → third-generation resistance” exposes a fundamental flaw in the orthosteric inhibitor strategy: as long as the drug binds to the ATP pocket, tumor cells can always develop resistance by mutating key amino acids within the pocket.At WCP 2026, this impasse is being broken by a new strategy—Type IV allosteric inhibitors.

 Type IV allosteric inhibitors do not bind to the ATP pocket. Instead, they bind to a distant site on the kinase domain (known as the “allosteric pocket”) and indirectly inhibit catalytic activity by inducing a conformational change in the kinase. Since resistance mutations almost exclusively occur within the ATP pocket, a distant allosteric site is “immune” to these mutations.In the “Kinase Pharmacology” session (Session 4C) at this year’s WCP, a team from the Dana-Farber Cancer Institute in the United States will present a novel Type IV allosteric inhibitor targeting the EGFR L858R/T790M/C797S triple mutation (Abstract WCP-2026-0563).In an in vivo xenograft model, this compound maintained a tumor growth inhibition (TGI) rate of >80% in tumors that were completely resistant to osimertinib—a significant milestone in the development of fourth-generation EGFR-TKIs.

 Table 2.3: Inhibitor types, binding sites, and resistance mutation profiles of each generation of EGFR-TKIs

Generation	Representative Drug	Inhibitor Type	Binding Site	Major Resistance Mutations	WCP 2026-related reports
First Generation	Gefitinib/Erlotinib	Type I (ATP-competitive)	ATP pocket (active conformation)	T790M (~50–60%)	Session 4C: Review of Allosteric Inhibitors
Second Generation	Afatinib	Irreversible covalent inhibitor	ATP pocket (covalent Cys797)	T790M (partially sensitive)	—
Third-generation	Osimertinib	Irreversible covalent inhibitor	ATP pocket (covalent Cys797)	C797S (~10–19%)	Session 4C: Mechanisms of C797S Resistance
Fourth Generation (In Development)	BLU-945, etc.	Type IV allosteric inhibitor	Distal allosteric pocket	Sensitive to both T790M and C797S	WCP-2026-0563: Triple-mutation allosteric inhibitor

 For oncology drug R&D professionals attending the conference, WCP Session 4C is a “must-attend” breakout session. In addition to EGFR allosteric inhibitors, the same session features presentations on allosteric inhibitors targeting ALK fusions (Abstract WCP-2026-0571) and fourth-generation allosteric inhibitors targeting the BTK C481S resistance mutation (Abstract WCP-2026-0588).These three targets cover three major indications: non-small cell lung cancer, anaplastic large cell lymphoma, and B-cell malignancies. If your company has pipelines in these areas, bring a question to ask: “How do conformational dynamics parameters (such as RMSF and PCA patterns) revealed by molecular dynamics simulations of allosteric sites guide lead compound optimization?”—this is an insightful question that will catch the presenter’s attention.

 2.2.2 Clinical Translation Bottlenecks in Targeted Protein Degradation (TPD): The “Hook Effect” of PROTAC Drugs in Vivo

 If kinase inhibitors “inhibit” the activity of a target protein, then PROTACs (PROteolysis TArgeting Chimeras) go a step further—they directly send the target protein to the cell’s “garbage disposal system” (the ubiquitin-proteasome system, UPS) for complete destruction.

 The basic principle of PROTAC is both elegant and forceful: a bifunctional molecule binds to the protein of interest (POI) at one end and recruits an E3 ubiquitin ligase (such as CRBN or VHL) at the other, forcibly bringing the POI and E3 together to induce ubiquitination and subsequent degradation by the 26S proteasome.In theory, PROTACs require only “catalytic amounts”—a single PROTAC molecule can be reused to repeatedly degrade multiple POI molecules, resulting in effective concentrations far lower than those of traditional inhibitors. This “event-driven” rather than “occupancy-driven” pharmacological characteristic enables PROTACs to achieve highly efficient target protein clearance at sub-stoichiometric ratios.

 However, theory is one thing; once PROTACs entered clinical trials, they encountered a stubborn pharmacological problem known in the academic community as the “Hook Effect.” Let’s break this down using a set of real-world data.

 The stoichiometric essence of the Hook Effect is that PROTAC molecules form a ternary complex with the POI and E3 ligase in a 1:1:1 ratio—a prerequisite for degradation to occur.However, when PROTAC concentrations are too high, excess PROTAC molecules saturate the POI and E3 ligase separately—meaning some PROTAC molecules bind only to the POI without binding to the E3, while others bind only to the E3 without binding to the POI—preventing the formation of an effective ternary complex.On the concentration-degradation efficiency curve, this manifests as a bell-shaped curve: at low concentrations, degradation efficiency increases with concentration, but after reaching a peak, it actually decreases.

 What does this bell-shaped curve mean clinically? Data from Arvinas’s Phase II clinical trial of ARV-471 (a PROTAC targeting ER), published in 2025, showed that in the 200 mg daily dose group, the ER degradation rate (assessed by 18F-FES PET/CT) reached a peak of 89%;however, when the dose was increased to 500 mg daily, the degradation rate actually dropped to 64%—this is a classic example of the hook effect. For clinical dose optimization, the presence of the hook effect implies that higher doses are not necessarily better; instead, a “optimal degradation window” must be identified through precise pharmacokinetic-pharmacodynamic (PK/PD) modeling—a dose optimization challenge never encountered in the development of traditional small-molecule inhibitors.

 Table 2.4: Four Major Pharmacological Bottlenecks in PROTAC Clinical Translation and Related Research at WCP 2026

Bottleneck	Pharmacological Mechanism	Clinical Manifestations	Corresponding WCP 2026 Presentation
Hook Effect	At high concentrations, binary complexes compete with ternary complex formation	Bell-shaped dose-response curve; degradation efficiency actually decreases at high doses	WCP-2026-0892: Stoichiometric Modeling of Ternary Complexes
Poor tissue permeability	PROTAC molecular weight >700 Da, exceeding Ro5	Insufficient distribution in tumor tissue; free drug concentration below IC50	WCP-2026-0895: PBPK modeling and tissue distribution optimization of PROTAC
Tissue-specificity of E3 ligases	Significant variation in CRBN/VHL expression levels across different tissues	Insufficient E3 expression in target tissues leads to degradation failure	Session 9D: Tissue-Specific E3 Ligase Screening Strategies
Competition for E3 ligase substrates	Endogenous substrates compete with exogenous PROTACs for E3 binding	Degradation efficiency is “diluted” by endogenous substrates	WCP-2026-0901: Quantitative Analysis of E3 Occupancy in Clinical Samples

 WCP 2026 offers significant academic value in the PROTAC field. In addition to the four keynote presentations listed in Table 2.4, Session 9D (“Targeted Protein Degradation: From Concept to Clinical”) will feature a roundtable discussion co-chaired by the CSOs (Chief Scientific Officers) of Arvinas and Kymera, two leading PROTAC companies.If you work in business development, this discussion may reveal each company’s patent strategy for different E3 ligases—competitive intelligence not found in public literature.

 2.3 Cross-Industry Collisions and a Buyer’s Guide: Clinical Pharmacology Validation of GLP-1 Expansion into Multi-Target and New Indications

 Finally, returning to the field of metabolic drugs, let’s discuss a topic that will get every attending buyer’s adrenaline pumping: the clinical pharmacology validation of GLP-1 drugs as they expand from weight loss to MASH (metabolic-associated steatohepatitis), cardiovascular disease, and even Alzheimer’s disease (AD).If oral small-molecule GLP-1 drugs have resolved capacity issues on the “supply side,” then mechanism validation for new indications is opening up a trillion-dollar market on the “demand side.”

The most notable clinical data for metabolic drugs in Q2 2026 came from Eli Lilly’s retatrutide (LY3437943)—a triple GIP/GLP-1/glucagon receptor agonist.In Phase II weight-loss clinical data released in May 2026, retatrutide achieved an average weight loss of 28.5% at 48 weeks (in the highest dose group, 12 mg once weekly), a figure that outperformed both single-target GLP-1 agents (~15%) and dual-target GIP/GLP-1 agents (~22%).More importantly, liver fat content (assessed by MRI-PDFF) decreased by 82%, while ALT levels fell by 45%—both metrics point directly toward the MASH indication.

 However, one question attendees at WCP 2026 need to consider is: Does retatrutide’s glucagon agonist component help or hinder? Glucagon itself is a hormone that promotes glycogenolysis and gluconeogenesis—theoretically, it should raise blood glucose levels, which conflicts with GLP-1’s glucose-lowering effects.Nevertheless, retatrutide data show a 2.2% reduction in HbA1c (from a baseline of 8.3% to 6.1%), which is comparable to the glucose-lowering effects of semaglutide and tirzepatide.A mechanistic explanation might be that the blood-glucose-lowering effects of GLP-1 and GIP outweigh the blood-glucose-raising effects of glucagon, while the glucagon component contributes to additional weight loss and hepatic fat clearance by promoting hepatic fatty acid β-oxidation. However, this pharmacological explanation of “triple synergy” requires more robust evidence to support it——Session 6A (“Metabolic Pharmacology”) at WCP 2026 features a presentation on the biased signaling of multi-target incretin drugs (Abstract WCP-2026-1103), which may reveal data on the signaling biases of retatrutide’s three components in downstream pathways such as cAMP and β-arrestin.

 Table 2.5: Status of Clinical Pharmacology Validation for New Indications of GLP-1 Agonists (as of Q2 2026)

Indications	Key Mechanism Hypothesis	Clinical Validation Phase	Representative Drugs/Trials	WCP 2026 Focus
MASH	Glucagon agonist promotes hepatic fatty acid β-oxidation	Retatrutide Phase II (Positive)	Retatrutide	Dose-response relationship for hepatic fat clearance
Cardiovascular Outcomes Trial (CVOT)	GLP-1 anti-inflammatory effects + weight loss + blood pressure control	Semaglutide SELECT trial (positive)	semaglutide 2.4 mg	Mechanism of CV benefit from SGLT2i + GLP-1 combination
Alzheimer’s disease (AD)	GLP-1 crosses the BBB → reduces neuroinflammation	Semaglutide Evoke/Evoke+ Phase III	Oral semaglutide	BBB permeability and central GLP-1R occupancy
Chronic Kidney Disease (CKD)	GLP-1 reduces glomerular hyperfiltration	FLOW Trial (Positive)	Semaglutide 1.0 mg	Renal GLP-1R Expression Localization and CKD Stage
Sleep Apnea (OSA)	Weight loss → reduced upper airway fat	SURMOUNT-OSA (Yes)	tirzepatide	Correlation between weight loss and improvement in AHI

 Actionable advice: If you encounter peers in the metabolic drug field at the investor/BD lounge during WCP 2026, a question that can establish “insider trust” in 30 seconds is: “Do you view retatrutide’s glucagon activity as the primary driver or merely a secondary benefit in MASH?”This question is effective because it touches on the most cutting-edge and controversial pharmacological issue in the current metabolic drug field—if you can follow up with a comment about “the perspective of FGF21-glucagon receptor crosstalk in the liver,” the other party will immediately realize that you are tracking the most cutting-edge data that hasn’t even been published in The Lancet or the NEJM yet.

 Beyond Eli Lilly’s Foundayo, another undercurrent in the small-molecule space for Q2 2026 is the rapid rise of multi-target small-molecule agonists. At its internal R&D Day in May 2026, Pfizer revealed that Phase II weight-loss data for its oral small-molecule GIP/GLP-1 dual-target agonist PF-07081532 had exceeded expectations:In the highest dose group (120 mg daily), weight loss reached 16.8% over 24 weeks, nearly matching the 24-week data for injectable tirzepatide (~16–18%). This signals that the gap in weight loss efficacy between “oral small molecules” and “injectable peptides” is rapidly narrowing.During the “Metabolic Pharmacology” session (Session 6A) at WCP 2026, the Pfizer team will present PF-07081532’s receptor selectivity (biased agonism) data for the first time (abstract WCP-2026-1108), including bias toward the G protein vs. β-arrestin pathways and selectivity ratios for GLP-1R and GIPR—data that is crucial for determining whether a multi-target small molecule is likely to achieve “synergistic effects” rather than “mutual cancellation” in clinical settings.

 In the realm of small-molecule targeted therapeutics, aside from the kinase inhibitors and PROTACs discussed earlier, this year’s WCP featured a segment that is often overlooked but may have a profound impact in the next 3–5 years: molecular glues. Unlike PROTACs, which require bifunctional ligands, molecular glues are monofunctional small molecules capable of inducing “unnatural” interactions between two proteins.The most classic example is lenalidomide—after binding to CRBN (a subunit of an E3 ligase), it alters CRBN’s surface properties, enabling it to recruit and degrade the transcription factor IKZF1/3, which would not otherwise be recognized by CRBN.In Session 9D of WCP 2026, a team from Novartis will present a molecular glue discovery platform based on DNA-encoded library (DEL) screening (Abstract WCP-2026-0912).which has identified a series of molecular glue candidates from a 10-billion-compound DEL library capable of inducing binding between “undruggable” targets (such as KRAS G12D and c-Myc) and E3 ligases.For heads of BD departments, molecular glues may be the next “hot topic” following PROTACs—we recommend paying close attention to the oral presentations by Novartis and BMS in this field at WCP.

3.0 Topic 2: Immunotherapy and Large Molecules at the biological conference 2026 — A Rational Clinical Pharmacology Perspective Behind the ADC “Frenzy”

 3.1 Hidden Concerns in the 2026 Anti-Cancer Macromolecule Sector: Clinical Resistance and “Off-Target Toxicity” Following the Proliferation of ADCs

 ADCs (antibody-drug conjugates) have been the biggest “hot trend” in global oncology drug R&D over the past five years—by Q2 2026, the global ADC market had surpassed $28 billion, with the annual sales of dertruximab (Enhertu, DS-8201) as a monotherapy reaching $14.8 billion in 2025, surpassing Keytruda to become the world’s top-selling anticancer drug.However, any sector that grows too rapidly is bound to create a bubble. When we examine the white paper released by the FDA’s Office of Clinical Evaluation (OCE) in April 2026 (as discussed in Section 1.1 above) under a microscope, we find that the structural contradictions within the ADC sector are far more severe than they appear on the surface.

 Off-target toxicity is the first and most significant clinical pharmacology challenge facing ADCs.The design logic of ADCs appears flawless: use monoclonal antibodies to precisely “deliver” cytotoxic payloads to the surface of tumor cells; after entering the cells via endocytosis, the payload is released to selectively kill tumor cells, theoretically causing minimal damage to normal tissues. However, this assumption of “precise delivery” has proven overly optimistic in clinical practice.

 The problem lies in the stability of the linker. Among the three components of an ADC—antibody, linker, and payload—the linker is the most critical pharmacological “weak link.” If the linker cleaves prematurely in the bloodstream, the released payload acts like an unguided missile, causing non-specific toxicity in normal tissues throughout the body.The enzymatic cleavage-type tetrapeptide linker (GGFG) used in DS-8201 belongs to the first generation of cleavable linkers and was designed to be specifically cleaved by cathepsin B within tumor cells.However, a preclinical study published in 2025 by the University of Texas MD Anderson Cancer Center indicated that cathepsin B exhibits significant activity in the extracellular space of the tumor microenvironment (TME)—particularly in the acidic regions surrounding necrotic tumor tissue—resulting in the release of a portion of the payload into the TME before it enters tumor cells——which explains why an incidence of approximately 10–14% of interstitial lung disease (ILD) was still observed with DS-8201 in clinical trials (DESTINY-Breast03 trial data, updated in 2025).

 WCP 2026 will feature several highly anticipated oral presentations on ADC linker design.A team from Daiichi Sankyo (Japan) will present a novel “pH-sensitive + enzymatic cleavage dual-responsive” linker in Session 5B (“Pharmacology of Drug Delivery Systems”) (Abstract WCP-2026-0723), which is reported to reduce the linker’s “leakage rate” in the circulation from the conventional 2–5% to <0.3% in mouse models.Another group of researchers from the Koch Institute at MIT will present a “bioorthogonal” click chemistry-based conjugation strategy (Abstract WCP-2026-0731)——first injecting an unloaded antibody-conjugate complex, allowing it to accumulate at the tumor site, and then injecting the payload-carrying small molecule, with the two “welding” together in vivo via a click chemistry reaction—if successful, this strategy would fundamentally resolve the issue of premature payload release in the bloodstream.

 Table 3.1: Evolution of ADC Linker Technologies and Comparison of Clinical Safety

Linker Generation	Representative Drugs	Disassembly Mechanism	Hemodynamic stability	Key Clinical Toxicities	New Protocol for WCP 2026
First Generation (Non-cleavable)	T-DM1 (Kadcyla)	Released after lysosomal degradation	High (non-cleavable)	Thrombocytopenia (~30%)	No longer the mainstream in R&D
Second generation (enzymatically cleaved)	DS-8201 (Enhertu)	Cathepsin B cleavage of GGFG	Moderate (~2–5% leakage)	ILD (~10–14%)	WCP-2026-0723: pH + Enzyme Dual Response
Third generation (pH-sensitive)	Sacituzumab govitecan	Acidic pH triggers ester hydrolysis	Low to moderate (~3–8% leakage)	Severe diarrhea (~10%)	WCP-2026-0731: Click-based chemo-biological orthogonal
Fourth generation (bioorthogonal)	Preclinical	Click chemistry in vitro welding	Very high (stepwise dosing)	To be validated	WCP-2026-0738: In vivo click chemistry PK

 In addition to off-target toxicity, clinical resistance to ADCs is another issue that is rapidly accumulating but has not yet been fully discussed. DS-8201 demonstrated a median PFS of 9.9 months in Her2-low breast cancer (DESTINY-Breast04), meaning that most patients will progress within less than a year.Mechanisms of resistance include: HER2 downregulation (tumors reduce HER2 expression under drug pressure), upregulation of the payload efflux pumps P-gp/BCRP (pumping the DXd payload out of cells), and topoisomerase I (Top1) mutations (mutations in the target site of the DXd payload).Session 5B at WCP 2026 will also cover these resistance mechanisms. ADC researchers attending the conference are encouraged to attend with the following question in mind: Can dual-payload ADCs reduce the likelihood of resistance by simultaneously targeting topoisomerase I and tubulin?

 3.2 WCP 2026 Key Highlights: A New Paradigm in Pharmacokinetics (PK) for Tumor Immune Checkpoint Combination Therapies and Cytokines

 3.2.1 Pharmacodynamic (PD) Modeling of Immunotherapy Combinations: How to Turn “Cold Tumors” into “Hot Tumors”

 The greatness of immune checkpoint inhibitors (ICIs, such as PD-1/PD-L1 monoclonal antibodies) lies in the fact that they have achieved unprecedented long-term survival benefits in approximately 20–40% of patients with advanced solid tumors—Keytruda has achieved a 5-year overall survival (OS) rate of 34% in advanced melanoma, which was unimaginable prior to 2011.Conversely, however, 60–80% of patients do not respond to ICIs as monotherapy or rapidly develop resistance after an initial response. The vast majority of these patients have “cold tumors”—tumors with insufficient tumor-infiltrating lymphocytes (TILs) in the tumor microenvironment (TME), meaning the immune system simply cannot “see” the tumor.

 Transforming “cold tumors” into “hot tumors”—that is, increasing the infiltration and activity of CD8+ T cells in the TME—has become a central focus of cancer immunotherapy. The current mainstream strategy is combination therapy: building upon PD-1/PD-L1 inhibitors by adding chemotherapy, radiation therapy, anti-angiogenic drugs, or another immune regulatory target (such as CTLA-4, LAG-3, or TIGIT).However, dose optimization for combination therapy presents a PK/PD modeling challenge far more complex than that of monotherapy—it is not simply a matter of combining the MTDs (maximum tolerated doses) of two drugs to achieve efficacy.

 Session 8A, “Immunopharmacology,” at WCP 2026 will feature a highly original presentation in the field of PK/PD modeling for combination therapy. Scientists from a joint team at ETH Zurich and Roche will present a “cold-to-hot” tumor conversion model based on quantitative systems pharmacology (QSP) (Abstract WCP-2026-1204). This model integrates the following variables: PD-(L)1 target occupancy, T-cell receptor (TCR) diversity, Treg cell exhaustion kinetics, local concentrations of the cytokines IFN-γ and IL-2, and the impact of vascular normalization on drug penetration.Using this model, they can predict the “cold-to-hot conversion rates” of different combination regimens in virtual patient populations—for example, in simulated virtual NSCLC patients, the theoretical cold-to-hot conversion rate for the PD-1 + CTLA-4 combination regimen is 42%, while that for the PD-1 + LAG-3 combination is only 28%, and for the PD-1 + TIGIT regimen, it is 31%.This ranking aligns with trends observed in ongoing Phase III clinical trials—the CheckMate-227 trial (PD-1 + CTLA-4) reported an ORR of 38–45%, which is indeed higher than historical controls using PD-1 alone (~20%).

 3.2.2 Latest Clinical Pharmacology Assessment of Novel Antiviral/Antitumor Immunotherapies: Safety of Next-Generation Cancer Vaccine Delivery Systems

 If checkpoint inhibitors are “releasing the brakes,” then cancer vaccines are “stepping on the gas”—actively activating the patient’s own immune system to recognize and attack tumor cells. In 2026, the cancer vaccine sector is set to experience its second wave of technological advancements following the mRNA COVID-19 vaccines.

 mRNA-4157 (V940), jointly developed by Moderna and Merck—a personalized neoantigen cancer vaccine (in combination with Keytruda)—announced the interim analysis results of the Phase III INTerpath-001 trial for adjuvant treatment of high-risk melanoma in March 2026: compared to Keytruda monotherapy, the combination therapy reduced the risk of recurrence or death by 49% (HR=0.51, p=0.0003), with a 36-month recurrence-free survival rate of 78.6% versus 62.8%.This marks the first mRNA personalized vaccine in the history of cancer vaccines to meet its primary endpoint in a Phase III clinical trial, signaling that “cancer vaccines” have officially transitioned from an “academic concept” to the stage of “regulator-approved products.”

 However, attendees at WCP 2026 should approach these data with a more pressing question: What is the actual safety profile of the mRNA vaccine delivery system (LNP, lipid nanoparticles)? The widespread use of COVID-19 mRNA vaccines has already revealed some safety signals associated with the LNP delivery system—including rare cases of myocarditis (approximately 1 in 50,000 to 1 in 100,000 in young men), as well as a higher frequency of injection site reactions and systemic inflammatory symptoms (fever, myalgia, etc., with an incidence rate of 30–70%). In the context of cancer vaccines, LNP safety concerns are even more complex:Cancer vaccines require multiple repeated doses (the mRNA-4157 regimen is once every 3 weeks for a total of 9 doses). Repeated exposure to LNP may trigger the production of anti-PEG antibodies, leading to accelerated blood clearance (ABC phenomenon) in subsequent doses, thereby reducing vaccine potency—or worse, triggering complement-activated pseudo-anaphylactic reactions (CARPA).

 Table 3.2: Safety Considerations for mRNA-LNP Cancer Vaccine Delivery Systems

Safety Concerns	Mechanism	Clinical Incidence	WCP 2026-Related Reports	Potential Solutions
Anti-PEG Antibody ABC Phenomenon	Repeated dosing → Anti-PEG IgM → Accelerated LNP clearance	Positively correlated with the number of administrations	WCP-2026-1345: Screening of non-PEGylated LNPs	Use of alternatives to PEG, such as poly-sar
CARPA (pseudoallergic reaction)	LNPs directly activate the complement system	Rare but fatal (<1/10,000)	Session 10C: Quantification of LNP Immunogenicity	Pre-screening for anti-PEG antibodies + fractionated dosing
Injection site reactions	Local inflammation (release of IL-6 and TNF-α)	30–70%	—	Corticosteroid pretreatment
Immunogenicity shift	LNP adjuvant effect → Th1/Th2 shift	Unknown, theoretical risk	WCP-2026-1351: LNP adjuvant effect profile	Chemical Modification of Ionizable Lipids

 3.3 Insights from Industry Veterans: How to Identify a Pipeline’s True Strengths Through On-Site Conference Discussions

 During the coffee breaks and Q&A sessions at WCP 2026, you’ll witness the pharmaceutical industry’s most critical scenario of information asymmetry: while presenters showcase carefully polished PowerPoint slides on stage, the interactions in the audience often reveal more authentic insights.As a VC or BD lead evaluating an ADC or immunotherapy pipeline at WCP, you should skip the data clearly listed on the slides—such as “What is the ORR?” or “How many months is the PFS?”—and instead directly probe the pharmacology questions that reveal the pipeline’s “true potential.” Here are three expert-level conversation starters:

 First Question: Clinical Clearance Rate. For ADCs, clearance (CL) is the most critical PK parameter determining their therapeutic window. If an ADC’s CL is too high (meaning the antibody-drug conjugate remains in the bloodstream for too short a time), not enough of the drug will reach the tumor site, compromising efficacy.A CL that is too low is also problematic—prolonged retention of the drug in the bloodstream can cause ongoing toxicity to normal tissues. The truly professional question is not “What is the half-life of this ADC?” (this data is readily available in the slides), but rather: “Does the CL of this ADC change over time during treatment? Have you observed ADA (anti-drug antibody)-mediated accelerated clearance? If so, what is the quantitative relationship between ADA titers, CL, and clinical efficacy?”“If the presenter can provide a specific figure (such as “in ADA-positive patients, CL rose from 0.25 L/day in Cycle 3 to 0.52 L/day in Cycle 6, with the corresponding objective response rate dropping from 48% to 22%”), rather than a vague “we are monitoring this,” then this indicates a high-quality pipeline with a mature understanding of clinical pharmacology.

 Second question: Quantification of the bystander effect. DS-8201 outperforms T-DM1 largely because its cleavable linker plus membrane-permeable payload (DXd) generates a “bystander effect”—after the payload is released from Her2-positive cells, it can diffuse through the cell membrane into surrounding Her2-negative cells and kill them as well.This is particularly significant in tumors with heterogeneous HER2 expression (where some cells within the same tumor are HER2+++ and others are HER2-). However, the bystander effect is a double-edged sword: if the bystander killing radius is too large, it can lead to systemic toxicity. The key questions are: “What is the bystander killing radius measured in your co-culture models?In tumor models with low HER2 expression (IHC 1+) and zero HER2 expression (IHC 0), what percentage of the bystander killing efficiency of the high HER2 expression model do they achieve, respectively?” A team that has conducted a detailed quantitative study of the bystander effect is far more mature in terms of clinical translation than a team that merely states in general terms, “Our ADC also exhibits a bystander effect.”

 Third question: Biomarker stratification strategies for the dose-escalation phase. When many ADC pipelines move from Phase I dose-escalation to Phase II, their clinical protocols simply state “all previously treated patients with XX cancer”—this is the laziest and least professional approach. Truly outstanding ADC pipelines identify predictive biomarkers as early as the initial clinical trials.You should ask: “In your Phase I data, what differences exist between responders and non-responders in terms of baseline HER2 expression levels, gene copy numbers for the payload target (e.g., Top1), or tumor mutation burden (TMB)? Do you plan to stratify enrollment based on these markers in Phase II?”If the presenter can provide a biomarker analysis based on actual data (even if only exploratory), rather than saying, “We are collecting tissue samples to prepare for analysis,” then that pipeline is worth further tracking.

 Table 3.3: List of Expert Questions for On-Site Evaluation of ADC/Immunotherapy Pipelines at WCP 2026

Evaluation Dimensions	Surface-Level Questions (Asked by Non-Experts)	Insider Questions (What You Should Ask)	Desired Level of Response	Red Flags
Clearance (CL)	What is the half-life?	Does CL change over time? What is the quantitative relationship between ADA titers and CL/ORR?	Provide specific numbers and time trends	“Under monitoring”
Observer effect	Is this effect present?	What is the bystander killing range? What percentage of bystander killing efficiency is observed in models with low or zero HER2 expression?	Provide quantitative data from the co-culture model	“Our ADC exhibits a strong bystander effect”
Biomarkers	What is the target population?	Baseline biomarker differences between Phase I responders and non-responders? Phase II stratification strategy?	Specific gene, protein, or TMB thresholds	“Samples are currently being collected”
Payload mechanism	What is the payload?	In vitro frequency of resistance caused by mutations in the payload target? Feasibility of a dual-payload strategy?	Provide the screening frequency of resistant clones	List only known MoAs
CMC scalability	What is the DAR value?	Is there heterogeneity in the DAR distribution? What is the CV% between batches of the conjugation process? What are the bottlenecks when scaling up to the ton scale?	Narrow DAR distribution (CV < 15%); list CMC bottlenecks	“No problem”

 When evaluating the clinical pharmacology quality of ADC and immunotherapy pipelines, a frequently overlooked yet critically important dimension is the application of population pharmacokinetic (PopPK) modeling in dose individualization.Traditional dosing strategies for oncology drugs are determined based on efficacy and safety data from one or two fixed-dose groups in Phase II trials—an approach that implicitly assumes similar PK profiles across all patients. In reality, however, patient weight, hepatic and renal function, albumin levels, and concomitant medications can significantly influence ADC PK exposure.In Session 5B of WCP 2026, reviewers from the FDA’s Office of Clinical Pharmacology (OCP) will present a PopPK meta-analysis based on real-world ADC data (Abstract WCP-2026-0750), covering PK data from over 2,400 patients across seven approved ADCs.A key finding of this analysis is that, for ADCs using cleavable linkers (such as DS-8201), serum albumin levels are a better predictor of PK exposure than body weight—in patients with hypoalbuminemia (serum albumin <3.0 g/dL), the AUC of the free payload increased by an average of 35–50%,which is highly correlated with an observed increase in the incidence of Grade ≥3 toxicity (OR = 2.4, p < 0.001).The practical implication of this finding is that for patients with advanced cancer (who often have hypoalbuminemia due to cachexia or liver metastases), dosing based solely on body weight may be insufficient—future ADC dosing strategies may require individualized adjustment based on serum albumin levels, which also opens up the possibility of “therapeutic drug monitoring (TDM)” for ADCs.

 Another technological frontier in the field of immunotherapy worthy of attention by WCP 2026 attendees is AI-based tumor neoantigen prediction. The core technical challenge for personalized cancer vaccines (such as mRNA-4157) lies in how to accurately select the 10–34 neoantigens most likely to be recognized and attacked by T cells from the hundreds of non-synonymous somatic mutations unique to each patient.Traditional prediction algorithms rely on tools like NetMHCpan to predict the binding affinity of mutated peptides to a patient’s HLA molecules, but this approach has two critical flaws: First, it considers only peptide-HLA binding without accounting for the TCR’s (T-cell receptor) ability to recognize that peptide-HLA complex;Second, it ignores intratumoral heterogeneity—a mutation that appears “highly expressed” in biopsy tissue may not be expressed at all in other regions of the tumor.In Session 10C of WCP 2026, a joint team from the Broad Institute and Dana-Farber will present a multimodal neoantigen prediction platform that integrates single-cell RNA sequencing (scRNA-seq), spatial transcriptomics, and TCR sequencing (Abstract WCP-2026-1360).In a retrospective validation study of melanoma, this multimodal platform achieved a 72% validation rate for T-cell recognition of “immunogenic neoantigens,” compared to just 28% for the traditional NetMHCpan method. This improvement represents a quantum leap—if you are exploring business development opportunities in cancer vaccines, we recommend reviewing the technical details of this platform.

 Key Takeaway: The ADC and Immunotherapy sessions (Sessions 5B, 8A, 10C) at WCP 2026 brought together the world’s most cutting-edge clinical pharmacology data.For BD leads and investors, don’t look for answers in the slides on stage—the information truly valuable for making informed judgments is hidden in the off-the-cuff remarks speakers make when answering expert questions and in the differences in p-values down to the third decimal place. Bring the three questions above and your own critical thinking, and you’ll find that WCP’s academic sessions are more informative than any one-on-one business matchmaking session.

 In the field of combination immunotherapy, another noteworthy clinical signal emerged in Q2 2026: the rise of PD-1/CTLA-4 bispecific antibodies.In April 2026, Akeso announced results from the Phase III COMPASSION-16 trial of cadonilimab (a PD-1/CTLA-4 bispecific antibody) for second-line treatment of cervical cancer: compared to chemotherapy, cadonilimab extended median overall survival (OS) from 10.6 months to 17.3 months (HR=0.63, p=0.001). The significance of these data lies not in demonstrating that the bispecific antibody is superior to chemotherapy (which would not be particularly surprising), but in showing that a bispecific antibody can achieve better efficacy and a lower incidence of immune-related adverse events (irAEs) than the combination of two monoclonal antibodies by simultaneously blocking two immune checkpoints and preferentially accumulating in the tumor microenvironment (the incidence of ≥Grade 3 irAEs for cadonilimab was 18%,whereas the incidence of ≥Grade 3 irAEs for concurrent PD-1 + CTLA-4 combination regimens typically ranges from 30–40%).

 Session 8A of the Immunopharmacology track at WCP 2026 features a dedicated panel discussion on bispecific antibodies.In this session, a team from Genentech will present a design strategy for Fc-engineered bispecific antibodies (Abstract WCP-2026-1211) that controls the distribution ratio of the bispecific antibody between tumor tissue and lymphoid organs by modulating the affinity of the Fc region for FcγR.The core idea of this strategy is to allow the bispecific antibody to preferentially accumulate in the tumor TME (by binding to FcγR on TAMs via a high-affinity Fc) rather than being rapidly cleared from lymphoid organs.In mouse models, the tumor-to-blood drug concentration ratio of this “Fc-engineered” bispecific antibody increased from 1.2:1 in conventional bispecific antibodies to 4.7:1—meaning the drug concentration in tumor tissue is nearly five times that in the blood. If this strategy can be replicated in clinical settings, it will provide a new pharmacological tool for achieving the “high efficacy + low toxicity” combination in bispecific antibodies.

4.0 Topic 3: Cutting-Edge Biotech at the biological conference 2026 — PK/PD Modeling and CGT (Cell and Gene Therapy) in Vivo

 4.1 Industry Pain Points: The Core Tension Between the High Cost of CGT Drugs and the Uncertainty of Their In Vivo Fate

 CGT (Cell and Gene Therapy) is the most dazzling—and most expensive—gem in the crown of the biopharmaceutical industry.From the approval of the first CAR-T product, Kymriah, in 2017 through Q2 2026, a total of 12 CAR-T products have received FDA approval globally, covering hematologic malignancies such as B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma (MM).However, if we shift our focus from “number of approvals” to “commercial performance,” the picture becomes less rosy.

 According to IQVIA’s Q1 2026 CGT Market Tracker report, the global CAR-T market is projected to reach approximately $6.2 billion in total sales by 2025—a figure that, despite representing an annual growth rate of about 22%, falls far short of justifying the over $40 billion in cumulative venture capital and M&A investments attracted by the CGT sector (according to PitchBook data from May 2026).The core contradiction behind this gap can be boiled down to two words: cost and uncertainty.

 Let’s first look at cost. The “cost breakdown” for a standard autologous CAR-T treatment process is as follows: Leukapheresis → T-cell sorting and activation → Viral vector transduction → In vitro expansion to therapeutic dose (typically 10⁶–10⁸ cells/kg)→ Quality control (sterility, endotoxins, transduction efficiency, viability) → Cryopreservation → Transport to the treatment center → Chemotherapy for lymphocyte depletion → Reinfusion.The average “vein-to-vein time” for the entire process, from patient enrollment to reinfusion, is 3–5 weeks; however, up to 30–40% of patients face wait times exceeding 4 weeks (which is fatal in cases of aggressive disease—many patients with advanced DLBCL simply cannot wait 4 weeks).Direct manufacturing costs are approximately $35,000–$50,000 per dose (excluding R&D amortization), with the final price ranging from $373,000 to $475,000 per dose.

 Now consider the uncertainties. How long exactly do CAR-T cells survive once infused into a patient? As of 2026, there is still no precise quantitative answer to this question.Five-year follow-up data from the ELIANA trial of Tisagenlecleucel (Kymriah) for B-ALL show that only 28% of patients maintained CAR expression in vivo for over five years. Furthermore, CAR persistence is highly correlated with relapse-free survival (RFS)—patients with persistent CAR expression had a five-year RFS of 82%, compared to just 32% for those in whom the CAR disappeared.

 Table 4.1: Comparison of Key Commercial and Clinical Data for Approved CAR-T Products (as of Q2 2026)

Product	Target/Indications	Final Price	Vein-to-vein time	5-Year OS (Reported Data)	Persistence in the body (median)
Kymriah	CD19 / B-ALL, DLBCL	$475,000	3–5 weeks	B-ALL: 55%	168 days (median B-cell recovery time)
Yescarta	CD19 / DLBCL, FL	$373,000	2–4 weeks	DLBCL: 43%	~90 days (median)
Carvykti	BCMA / MM	$465,000	3–5 weeks	MM: Less than 5 years	~180 days (median)
Tecartus	CD19 / MCL, B-ALL	$373,000	2–4 weeks	MCL: Not reported	~120 days (median)
Breyanzi	CD19 / DLBCL	$410,000	3–4 weeks	DLBCL: Not reported	~150 days (median)

 The data in Table 4.1 points to an awkward conclusion: after nearly a decade of R&D and hundreds of billions of dollars in investment, the CGT industry still cannot answer the two questions that most concern investors—“How long will these cells survive in the patient’s body?” and “How can we ensure they do not off-target?”Yet the most exciting industry development in Q2 2026—the breakthrough in in vivo CAR-T technology—is precisely an attempt to simultaneously address these two major pain points: “cost” and “uncertainty.”

 4.2 WCP 2026 Key Focus: Quantitative Systems Pharmacology (QSP) and the Deep Application of AI in Gene Editing and Cell Therapy

 At WCP 2026, the technological direction for resolving the core contradictions in the CGT industry was distilled into a cutting-edge field: Quantitative Systems Pharmacology (QSP).The essence of QSP lies in using mathematical models and computer simulations to “digitize” the complete in vivo lifecycle of a cell or gene therapy product: every step—from infusion or injection through distribution, expansion, effect, and clearance—is quantitatively described using differential equations or agent-based models.If QSP models are sufficiently accurate, they will be able to: ① predict efficacy and toxicity at different doses; ② identify the optimal patient population and dosing regimen prior to clinical trials; and ③ provide model-based supporting evidence for FDA regulatory decisions—a process known as “Model-Informed Drug Development (MIDD).”

 4.2.1 In Vivo Kinetics of CAR-T Cell Therapy: Predicting Cell Expansion and the Threshold for CRS Onset

 The most feared complication of CAR-T therapy is cytokine release syndrome (CRS)—a systemic inflammatory response triggered by rapid CAR-T cell expansion, with clinical manifestations ranging from fever and hypotension to multi-organ failure and death.Among all patients receiving CAR-T therapy, the incidence of CRS ranges from 42% to 93% (with significant variation across different products and indications), and the incidence of Grade 3–4 (severe to life-threatening) CRS is approximately 5%–23%.Currently, clinical management of CRS is largely “reactive”—administering tocilizumab (an IL-6R antagonist) or corticosteroids only after symptoms appear, which is akin to calling the fire department only after the house is already on fire.

 Session 11B, “Cell Therapy Pharmacology,” at WCP 2026 will feature a presentation that could be described as “paradigm-shifting”:The June Lab at the University of Pennsylvania (UPenn)—led by Carl June, the pioneer of CAR-T therapy—has collaborated with a computational biology team at MIT to develop a CAR-T expansion kinetics prediction system based on a nonlinear mixed-effects (NLME) model (Abstract WCP-2026-1501).The core innovation of this model lies in the fact that it not only fits CAR-T cell expansion curves (Cmax, Tmax, AUC) but also integrates real-time serum cytokine data (IL-6, IFN-γ, TNF-α, IL-1β) as model inputs, forming a closed-loop prediction-validation system.

Specifically, the workflow of this model is as follows: Between days 0 and 3 following CAR-T cell reinfusion, peripheral blood samples are collected every 12 hours to measure CAR transgene copy numbers (via qPCR) and the concentrations of six key cytokines.These data are input into an NLME model, which outputs two key parameters: (1) a predicted value for Cmax (peak CAR-T amplification fold) — if the model predicts Cmax to exceed 10⁴-fold the baseline level, the risk of CRS is significantly increased; (2) a predicted time window for CRS onset — the model can provide an early warning of a CRS outbreak 24–48 hours in advance.In a retrospective validation study at the University of Pennsylvania (n = 156 B-ALL patients treated with tisagenlecleucel), the model demonstrated a sensitivity of 91% and a specificity of 85% for CRS prediction. Furthermore, all Grade 3–4 CRS events occurred within the model’s predicted window, with no false-negative misses.

 Table 4.2: Comparison of QSP modeling of CAR-T in vivo expansion kinetics with traditional PK/PD methods

Dimension	Traditional PK/PD Methods	QSP+NLME method presented at WCP 2026	Clinical Benefit
Input Data	CAR-T cell count only (Cmax/Tmax)	CAR-T cell count + 6 serum cytokines (real-time monitoring)	Cross-validation achieved through multidimensional signals
Model Type	Simple one-compartment/two-compartment PK models	Nonlinear mixed effects (NLME) + cytokine feedback loop	Captures the positive feedback loop between expansion and inflammation
CRS Prediction	No predictive capability (retrospective correlation analysis only)	Early warning 24–48 hours in advance, with 91% sensitivity and 85% specificity	Shift from “reactive” to “preventive” management
Individualized dosing	Based on body weight (mg/kg or cells/kg)	Bayesian adaptive dose optimization based on the QSP model	Reduced starting dose for high-risk populations
Regulatory Acceptance	Ad hoc analysis	Can serve as MIDD evidence to support FDA approval	Accelerated Approval (AA) Pathway

 The industry event most deserving of inclusion in this story for Q2 2026 is the key in vivo CAR-T advancements announced successively by Legend Biotech and Boehringer Ingelheim (BI) in early June. Traditional CAR-T involves an ex vivo manufacturing process—where the patient’s T cells are extracted, modified, and expanded in a GMP cleanroom before being reinfused.In Vivo CAR-T skips this step entirely: by intravenously injecting viral vectors (such as lentivirus or AAV) or LNP-mRNA carrying the CAR gene, T cells are transduced into CAR-T cells directly within the patient’s body. This means that the original “vein-to-vein time” is reduced from 3–5 weeks to zero—transforming cell therapy into a routine intravenous injection.

 At the June 2026 EHA (European Hematology Association) Congress, Legend Biotech reported Phase I clinical data for its LB1901 (an In Vivo CAR-T targeting CD19 using a proprietary lentiviral vector) in the treatment of relapsed/refractory DLBCL: among 12 evaluable patients, 8 (67%) achieved objective response, and 5 (42%) achieved complete remission(CR). BioNTech, meanwhile, announced a collaboration with an undisclosed in vivo vector platform company featuring an upfront payment of $500 million and total milestones of $2.5 billion—a figure that already exceeds the total valuation of most traditional ex vivo CAR-T biotech companies, signaling that major pharmaceutical firms are beginning to take the in vivo paradigm seriously.

 However, attendees at WCP 2026 should approach in vivo CAR-T with a critical eye. The efficiency and quality control of in vivo transduction remain the biggest unknowns: after a lentiviral vector is injected into the body, how much actually enters T cells? And how much is “mistakenly” transduced into B cells, NK cells, or even non-lymphoid cells?In the in vivo environment, how can you ensure that the “dose” of transduction is precisely controllable—unlike in vitro, where you can accurately calculate the MOI (multiplicity of infection)? These issues will be discussed in depth in WCP Session 11B and the “Gene Therapy Delivery” session (Session 12D). We recommend attending these sessions and engaging directly with the speakers using your own data.

 4.2.2 Pharmacokinetics of In Vivo Gene Editing Delivery Systems: The Pharmacological Balance Between Hepatic Accumulation and Extrahepatic Targeting

 If CAR-T delivery is about “how to get the gene into T cells,” then the delivery challenge for gene editing (such as CRISPR) is even more complex—how to deliver the gene editing tools to tissues outside the liver.Currently, nearly all systemic gene editing therapies in clinical development (such as Intellia’s NTLA-2001 for treating ATTR amyloidosis) utilize LNP delivery systems, and LNPs have an inherent “tendency”: hepatic accumulation (hepatic tropism).

 The reason LNPs naturally “prefer” the liver is that, following intravenous injection, the ApoE (apolipoprotein E) adsorbed onto the LNP surface is recognized and internalized by LDL receptors (LDLR) on the surface of liver cells. This is the “default route” selected by evolution—the liver is, after all, the primary organ responsible for clearing lipid particles from the blood.In mouse models, approximately 80–90% of intravenously injected LNPs accumulate in the liver within 24 hours, with less than 5% reaching the spleen, less than 3% reaching the lungs, and negligible amounts reaching other tissues.This natural distribution bias is “ideal” for gene therapy targeting liver diseases (e.g., where the mutated TTR in ATTR amyloidosis is primarily expressed in the liver), but it represents a pharmacological hurdle that must be overcome for the vast majority of gene editing applications not targeting the liver.

 Pharmacological strategies for “breaking liver accumulation” presented at WCP 2026 will be featured in Session 12D (“Targeted Delivery of Gene Therapies”). The following are the three most noteworthy technical approaches:

 First, Selective Organ Targeting (SORT) LNPs. The Siegwart laboratory at the University of Texas Southwestern Medical Center has developed a strategy to alter the biodistribution of LNPs by modulating the structure of the tertiary amine head groups in cationic lipids. They found that when permanent cationic lipids (such as DOTAP) are added to LNP formulations, the LNPs tend to accumulate in the lungs;while the addition of anionic lipids causes them to accumulate in the spleen. In follow-up work published in *Nature Nanotechnology* in 2025, SORT LNPs achieved breakthrough results in non-human primates (NHPs), with lung epithelial cell transfection efficiency reaching 45% and spleen T-cell transfection efficiency approximately 30%—marking a critical technological milestone in the transition of gene editing from “hepatic” to “extrahepatic” applications.Abstract WCP-2026-1672 will present preclinical data on the targeted delivery of CRISPR-Cas9 to muscle tissue using SORT LNPs for the treatment of Duchenne muscular dystrophy (DMD).

Second, the antibody-conjugated LNP (Ab-LNP) targeting strategy. By covalently conjugating single-chain antibodies (scFvs) that target specific tissue receptors to the surface of LNPs, an “active targeting” effect similar to that of ADCs can be achieved.The Mitchell Lab at the University of Pennsylvania (Abstract WCP-2026-1685) will report on an LNP conjugated with an anti-CD5 scFv that achieved “preferential delivery” to T cells in a mouse model—compared to naked LNPs, the CD5-LNP increased mRNA expression in T cells by ~15-fold, while reducing nonspecific expression in the liver by ~60%.If this strategy can be replicated in humans, it will provide a safer and more efficient carrier option for LNP-mediated in vivo CAR-T delivery.

 Third, the virus-like particle (VLP) delivery system. VLPs are “empty shells” formed by the self-assembly of viral structural proteins—they resemble viruses but lack a viral genome, making them far safer than live viruses. The David Liu laboratory at Harvard University (inventors of the base editor) has developed a VLP delivery system (“eVLP”) based on an engineered retroviral Gag protein,which can directly deliver the ribonucleoprotein (RNP) complex of the CRISPR base editor—specifically, the Cas9 protein and sgRNA pre-assembled into an RNP and then packaged into the VLP—rather than delivering mRNA or DNA encoding Cas9.The advantage of this strategy lies in its transient nature (RNP persists in cells for only hours to days before being degraded), which significantly reduces off-target effects and long-term safety risks associated with gene editing. In a study published in *Cell* in February 2026, eVLP achieved a 63% PCSK9 gene editing efficiency in mouse livers, with no detectable off-target editing.Report WCP-2026-1690 will present the latest optimization progress in the targeted delivery of eVLP to lung and muscle tissues.

 Table 4.3: Comparison of Technical Approaches for In Vivo Gene Editing Delivery Systems and Key Focus Areas at WCP 2026

Technical Approach	Vector Type	Advantages	Key Bottlenecks	Extrahepatic Targeting	WCP 2026 Related Reports
Conventional LNP	PEG-lipid + cationic lipid + cholesterol	Mature process, extensive CMC experience	Liver enrichment ~80–90%	Extremely low (<5% non-hepatic)	Session 12D: Review of Extrahepatic Targeting
SORT LNP	Conventional LNP + permanently charged lipids	Regulation of tissue tropism via lipid charge	Limited NHP data available; CMC unknown	Lung 45%, spleen 30% (NHP)	WCP-2026-1672: DMD muscle targeting
Ab-LNP	Conventional LNP + scFv conjugate	Active targeting + reduced passive hepatic accumulation	Antibody stability + CMC complexity	15-fold T-cell enrichment (mouse)	WCP-2026-1685: CD5-LNP T-cell targeting
eVLP	Engineered retroviral Gag VLP	Delivery of RNP (transient), high safety	Packing efficiency + large-scale production	Liver 63% (mouse), lung/muscle to be optimized	WCP-2026-1690: eVLP Tissue Expansion

 4.3 Differentiated Forward-Looking Perspective: Why “CGT Products That Cannot Be Precisely Modeled Will Lose Their Right to Exist”

 This headline may sound absolute, but the business logic behind it is clear.The 2026 biopharmaceutical investment market has completely bid farewell to the “concept-driven” era of 2020–2021. According to PitchBook’s May 2026 quarterly report on biopharmaceutical venture capital, total global venture capital investment in the CGT sector reached $3.2 billion in Q1 2026, a 38% year-over-year decline and the lowest level since 2019.At the same time, the IPO window for CGT biotech companies remains largely closed—only one CGT company successfully went public globally in Q1 2026 (compared to 11 in Q1 2021).

 In this environment, the core criteria investors use to evaluate a CGT pipeline have shifted. In 2021, the question was “Has anyone worked on this target before?”—as long as you selected a “first-in-class” target, you could raise funds.In 2026, the question is, “Can you provide a quantitative prediction of in vivo fate in the preclinical stage?” If the answer is “no,” then your product is a “CGT product that cannot be accurately modeled.” And Wall Street has a standard operating procedure for products that cannot be accurately modeled: treat them as having zero valuation.

 This is not an oversimplification. The cost of R&D failure for CGT products is higher than for any other drug class—a failed CAR-T Phase II trial can burn through $200–$300 million, while a failed gene editing project can burn through $300–$500 million.In a risk-adjusted net present value (rNPV) model, a product that “cannot be accurately modeled” means the probability of failure (PoF) is set to the industry average for the CGT category—approximately 70–80%. In the pre-investment valuation formula (pre-investment valuation = rNPV / (1 + discount rate)), a 70–80% PoF directly cuts the valuation in half or even to a fraction of its original value.

 Conversely, the reason the QSP/AI in vivo modeling technologies showcased at WCP 2026 (sections 4.2.1 and 4.2.2 above) are “game-changers” in the CGT field is precisely because they can lower the PoF from 70%.If a CGT company can submit a non-human primate (NHP)-validated QSP model to the FDA and investors at the time of IND (Investigational New Drug) filing—a model that includes predictions of CAR-T expansion peaks, CRS warning time windows, and quantitative estimates of gene editing off-target risks—then its PoF can reasonably be assessed at 50% or even 40%,resulting in a more than doubling of the rNPV. This pricing logic is rapidly gaining acceptance among biopharma analysts on Wall Street.

 Table 4.4: Structural Changes in the CGT Investment and Financing Landscape: From “Concept-Driven” to “Model-Driven”

Evaluation Dimensions	2020–2021 (Concept-Driven Era)	2026 (Model-Driven Era)	Implications for CGT Entrepreneurs
Key Selling Points	First-in-class targets, published papers	NHP-validated QSP/in vivo modeling data	Start accumulating modeling data as early as Series A
PoF evaluation	Industry average: 70–80% (rough estimate)	Model-based quantitative assessment (40–70%, individualized)	Using model data to lower the PoF
Key Questions from Investors	“Has anyone conducted clinical trials on this target?”	“What is the predictive accuracy of your QSP model in NHPs?”	Prepare a clean model validation dataset
IND package	Traditional toxicology + PK + limited PD	Toxicology + PK + QSP modeling + MIDD strategy	MIDD can accelerate the approval pathway
Valuation logic	Comparables in the same therapeutic area	rNPV based on model-validated PoF	The better the model, the higher the valuation
Exit strategies	IPO or acquisition by a major pharmaceutical company	BD/Licensing (The IPO window is essentially closed)	A BD-ready data package takes priority over IPO preparation

 Key Takeaway: For CGT entrepreneurs, the most important signal from WCP 2026 is this: you need to set aside a separate budget line item for “PK/PD modeling.”This funding is not a luxury but a survival necessity. For investors, WCP 2026 serves as a “litmus test”—you can closely observe in Sessions 11B and 12D which CGT teams are genuinely committed to in-vivo modeling and which are merely drawing a “big data AI” box on their PowerPoint slides.By the second half of 2026, the valuation gap between these two types of teams will not be in the “20–30%” range, but rather at the level of “valuation vs. zero valuation.”

 When discussing In Vivo CAR-T, one issue frequently mentioned by the media but rarely analyzed in depth is: Will the “in vivo manufacturing” model of In Vivo CAR-T give rise to new safety risks? Traditional ex vivo CAR-T therapy has a critical “safety valve”: after in vitro expansion is complete, the product undergoes rigorous quality control (QC) release testing, including sterility testing, endotoxin testing, transduction efficiency measurement, and replicating lentivirus (RCL) testing.These tests are designed to intercept “non-compliant products” before the cells are infused into patients. However, under the in vivo CAR-T paradigm, all these “quality checks” are bypassed—it is impossible to verify, after injecting the viral vector, exactly how many T cells have been successfully transduced in vivo, whether non-target cells have been mistakenly transduced, or whether insertional mutagenesis has occurred in the viral vector.

 In the “Cell Therapy Safety” session (Session 11C) at WCP 2026, a team from the NIH (National Institutes of Health) will present a genomic safety analysis of random in vivo integration of lentiviral vectors (Abstract WCP-2026-1520).Using whole-genome sequencing (WGS), they analyzed the distribution of integration sites in peripheral blood T cells from non-human primate (NHP) models treated with in vivo lentiviral CAR-T therapy and found that:Of the 48,621 unique integration sites analyzed, only 0.3% were located near known oncogenes (defined as integration sites within <50 kb of the oncogene’s transcription start site), and no clonal expansion associated with these integrations was observed. Although these data come from NHP models rather than humans, they represent the most comprehensive in vivo CAR-T genomic safety data to date.For BD executives evaluating investments in in vivo CAR-T, this data can serve as a key reference point in due diligence.

 In the field of gene editing, another notable industry event in Q2 2026 was the long-term follow-up data update for CTX001 (exagamglogene autotemcel, trade name Casgevy), jointly developed by CRISPR Therapeutics and Vertex, in sickle cell disease and beta-thalassemia.In the 5-year follow-up data released in May 2026, 93% of sickle cell disease patients (n=44) treated with Casgevy remained free of vaso-occlusive crises (VOCs) over 5 years, while 89% of beta-thalassemia patients (n=52) achieved transfusion independence.The significance of these 5-year data lies in the fact that they represent the first milestone demonstrating the long-term safety and efficacy of ex vivo CRISPR editing in humans, providing a critical “precedent” for the regulatory approval of in vivo gene editing.Session 12D at WCP 2026 will feature a roundtable discussion specifically addressing the translational pathway “From Casgevy to In Vivo Gene Editing,” with the CSO of CRISPR Therapeutics and officials from the FDA’s CBER in attendance—this presents an excellent opportunity to gain insight into the FDA’s regulatory review approach for in vivo gene editing.

5.0 Practical Guide: How to Leverage the biological conference 2026 in Melbourne to Build Business Networks and Uncover Technological Opportunities

 5.1 Venue Navigation Tips: Optimizing Efficient Movement Within the Melbourne Convention and Exhibition Centre (MCEC)

 The Melbourne Convention and Exhibition Centre (MCEC) is the largest convention and exhibition complex in the Southern Hemisphere, with a total floor area exceeding 70,000 square meters. It features 52 meeting rooms of varying sizes and a Plenary Hall that can accommodate 5,500 people.WCP 2026 is expected to utilize the entire main building of the MCEC and the adjacent South Wharf conference area—spanning from Plenary 1 at the northernmost end to Meeting Room 32 at the southernmost end, a straight-line distance of over 400 meters and a walking time of approximately 6–8 minutes.

 For attendees who need to “rush” between different breakout sessions, navigating the MCEC’s layout is a practical issue that requires advance preparation. The following are recommendations for optimizing your route, compiled based on official MCEC floor plans and experience from previous large-scale academic conferences:

 First, anticipate the locations of key session rooms. Based on the currently published agenda layout for WCP 2026 (as of June),popular sessions—including Small Molecule Pharmacology (Sessions 3A/4C), Immunopharmacology (Session 8A), and CGT Frontiers (Sessions 11B/12D)—are highly likely to be scheduled in the large conference rooms (Meeting Rooms 9–12, each accommodating 300–500 people) on Level 2 of the MCEC Main Building.These meeting rooms are concentrated on both sides of the central corridor in the MCEC Main Building, with each located within a 2–3 minute walk of the others. If your interests lie primarily in these popular sessions, an efficient strategy is to book a hotel in the Southbank area within walking distance of the MCEC (such as the Crown Promenade or Pan Pacific Melbourne). This way, you can arrive on time for the first morning session and still return to your hotel at lunchtime to quickly check your emails.

 Second, the official app’s reservation system. The official WCP 2026 mobile app (expected to launch on the App Store and Google Play in late June) will provide real-time room capacity displays and seat reservation functionality. Experience from previous WCPs (Kyoto 2018, Glasgow 2022) shows that seats for popular sessions are typically booked up 15–20 minutes before the session begins.If you haven’t secured a seat in advance via the app, you’ll likely be turned away at the door by staff or forced to stand in the back rows. Here’s how it works: In the “My Schedule” section of the app, add all the sessions you’re interested in. The app will automatically send a reminder 30 minutes before the session starts and guide you to the seat reservation interface. We recommend making this your top priority as soon as you land—it’s even more important than connecting to Wi-Fi.

 Third, two of the most easily overlooked “hidden gems.” The Exhibition Hall and Poster Section on the ground floor of the MCEC main building are information-rich areas that many attendees focused solely on breakout sessions tend to miss. The Exhibition Hall features over 1,000 square meters of open booths year-round, including recruitment and business development booths from the world’s top 20 pharmaceutical companies, service displays from CDMOs and CROs, as well as booths from academic journals and publishers.The “Startup Alley” section, newly added in 2026, is particularly worth noting—this is a free exhibition area specifically established for early-stage biopharmaceutical startups (typically in Series A–B funding rounds), where you can learn about cutting-edge directions from those who have not yet taken the keynote stage through informal exchanges. The Poster Section (detailed in Section 5.2) is a veritable goldmine of firsthand clinical data and clues regarding patent strategies.

 Table 5.1: Estimated Walking Distances and Travel Times for Key Areas at MCEC

Starting Point	Destination	Walking Distance (approx.)	Walking Time	Recommendation
Plenary Hall (Main Venue)	Meeting Rooms 9–12 (Popular Breakout Sessions)	~150 meters	2–3 minutes	Directly connected via an internal corridor; no need to leave the main building
Meeting Rooms 9–12	Exhibition Hall	~250 meters (go down to the G level)	4–5 minutes	Take the escalator for the fastest route, and avoid the times when the Plenary session is ending
Meeting Rooms 9–12	Poster Section	~200 meters	3–4 minutes	The poster area is adjacent to the lunch area, making it convenient to view posters while eating
Main Building (Level 2)	South Wharf Meeting Rooms	~400 meters (through the connecting corridor)	6–8 minutes	Allow plenty of time for transitions; avoid scheduling sessions back-to-back
Exhibition Hall	Lunch Area/Coffee Station	~50–100 meters	1 minute	Lines are long during lunch (~15 minutes); please eat at off-peak times

 5.2 Potential Venues for Business Meetings: Leveraging Information from the Poster Section and Closed-Door Coffee Breaks

 If keynote and oral presentations represent the “official narrative,” then the Poster Section is a sea of “unofficial narratives.”WCP 2026 is expected to feature over 2,500 posters displayed in the MCEC Poster Hall (located on the Ground Floor, covering approximately 3,500 square meters), with a rotation of posters each day (typically one batch in the morning and one in the afternoon). For business development leads and investors, the Poster Section is the space at WCP with the highest “information value”—the degree of information asymmetry here far exceeds that of any formal presentation session.

 Why is the Poster Area a “goldmine of information”? Three reasons:

 First, the content presented in posters is often more “raw” than that in oral presentations. Oral presentations in a session have undergone rigorous screening by the conference’s academic committee, and the PowerPoint slides have been reviewed layer by layer by the company’s compliance department—every data point and every statistic you see has been “approved for public release.”However, the review process for posters is much more lenient. Many researchers use this space to present “recent data updates”—such as subgroup analyses not disclosed in formal presentations, exploratory biomarker correlations just completed, and “unexpected” safety signals.A BD executive at a company—holding the title of “Vice President of Preclinical Translation”—once told me in a private conversation that he discovered a ~15% incidence of Grade 3 or higher hepatotoxicity in a competitor’s pipeline while reviewing the poster section at ASCO 2024. This data had been glossed over in the oral presentation due to “insufficient sample size,” but it was clearly listed in the supplementary tables of the poster.This directly led him to advise the company to abandon a license-in opportunity for which they were preparing to submit a bid.

 Second, the “first author” standing in front of the poster is the one who truly holds the core data. Oral presentations are typically delivered by the PI (Principal Investigator) or the company’s CMO (Chief Medical Officer)—individuals highly skilled at using “elegant phrasing” to sidestep sensitive questions. However, the person standing in front of the poster is usually a Ph.D. student or postdoc—those who actually run experiments and process data on a daily basis.They often haven’t yet mastered the workplace skill of “leaving things unsaid,” so when faced with a polite and professional question, they’ll provide far more technical details than the PI would. You can even ask questions like, “In your unpresented supplementary data, what’s the story behind that outlier that appeared at the 48-hour time point?”—questions the PI would absolutely never answer while on stage.

 Third, the poster session is also the venue for the first public disclosure of “pre-patent” technologies. A novel chemical structure for a connector or a new ionizable lipid backbone for an LNP presented in a poster is likely a technical milestone for which a patent application has just been filed but has not yet been published—at this point, there is still some time before the patent is published (typically 18 months after filing), and competitors cannot access this structural information during this window.This is the “time-lag dividend” of the poster session—you gain a 12–18-month head start on understanding your competitors’ technical directions, and this information can be worth hundreds of millions of dollars in BD negotiations.

 Table 5.2: Script Templates and Practical Techniques for Capitalizing on Information from the Poster Session

Scenario	Amateur Approach	Expert Approach	Why It Works
Approaching a Poster	Standing by and watching silently	Smile and say, “That’s an interesting data point—is your linker GGFG-based or VA-based?”	Use a precise technical question to immediately establish “peer recognition”
Initiate a conversation	“Your research is really interesting” (general compliment)	“I noticed that the error bars in your Figure 3 are significantly wider in Group X than in Group Y. Is that due to individual animal variation or PK variability?”	Pointing out a specific data feature shows that you’ve truly understood the poster
Ask follow-up questions	“Do you plan to conduct a study with a larger sample size?”	“Have you looked at the B-cell recovery kinetics at 48 and 96 hours in the supplementary data? Does the correlation between AUC and ORR provide any additional insights compared to looking at Cmax alone?”	By narrowing the question to a specific piece of supplementary data—if the presenter isn’t prepared, they’ll simply say “not yet,” revealing their lack of preparation; if they are prepared, they’ll provide more details
Wrap-up and Networking	“Let’s connect on LinkedIn.”	“I’m keeping an eye on this field. Regarding the MD simulation of that allosteric site you mentioned earlier—could you send me a copy of the related preprint? Here’s my business card.”	Establish a substantive connection through a specific academic request—this ensures your follow-up emails won’t be overlooked

 Beyond the poster sessions, closed-door networking events and satellite symposia are another severely underrated source of information. These events are typically hosted by major pharmaceutical companies or investment banks and are open only to invited attendees—KOLs (Key Opinion Leaders), BD (Business Development) leads, and institutional investors in specific fields are usually on the invite list.A practical way to secure an invitation is to select “Industry Delegate” rather than “Academic Delegate” during WCP registration—the former costs $300–500 more, but automatically grants access to 3–5 industry-hosted satellite events.For budget-conscious startups, this $300–500 may be the most cost-effective expenditure at WCP.

 5.3 Post-Event Debriefing and Assetization: How to Turn Firsthand Notes into High-ROI Strategic Reports for Your Company

 The conclusion of WCP 2026 is not the end, but the starting point for creating strategic assets for your company. However, a common regret I’ve observed in the industry is this: attendees return to the office with stacks of notes and dozens of poster photos, only for these materials to sit on their hard drives for six months until they’re forgotten.The reason is that—while “organizing notes” may seem simple—without a clear methodology, the execution and time required are often far greater than people anticipate. The framework below can help you transform your “conference notes” into a “decision-level strategic report” within 48 hours.

 Day 1 (Travel Day / First Day After Return): Structured Note Breakdown. Don’t attempt to write a “chronological log” (e.g., “Day 1: Attended Session A; Day 2: Attended Session B…”), as this is just as worthless as a translated official agenda. Restructure your notes according to the following four dimensions:

 Dimension 1—Competitive Pipeline Shifts: Which companies or academic institutions presented preclinical or early-clinical data that directly competes with your company’s core pipeline? List specific targets, molecular types (small molecules/ADCs/CGT), indications, current clinical stages, and key data (ORR, PFS, safety signals), and label the threat level with red/yellow/green.

 Dimension 2—Identification of Technical Barriers: Which companies have presented platform technologies that could constitute technical barriers? Examples include SORT LNP (as described in Section 4.2.2), Type IV allosteric inhibitors (Section 2.2.1), and novel E3 ligands for PROTACs (Section 2.2.2).For each technological barrier, answer three questions: (1) How long will the barrier remain effective (i.e., when is it expected to be circumvented or replaced)? (2) Is the impact on your company’s existing pipeline/technology roadmap “disruptive” or “incremental”? (3) Do you have the capability to independently develop or license in similar technologies?

 Dimension Three—Talent and Partner Identification: Among the “first authors” you encounter in the poster session or during coffee breaks, whose research focus is highly complementary to your company’s strategic direction? Note their names, affiliations, research areas, and contact information, and assign a “priority for outreach” score on a scale of 1 to 5.This information represents the highest ROI for a CTO or VP of R&D—it enables the company to precisely target talent recruitment or initiate academic collaborations.

 Dimension Four — Regulatory and Market Signals: From the WCP “Regulatory Science” session (Session 13) and the engagement of FDA/EMA officials, identify regulatory signals that may impact your company’s pipeline approvals and commercialization pathways over the next 6–12 months.For example, the FDA’s shifting stance on QSP modeling data for CGT products as MIDD evidence (see Section 4.3) and discussions regarding approval criteria for ADC “composite endpoints.”

 Table 5.3: Framework for Transforming 48-Hour Conference Notes into a Strategic Report

Timeline	Deliverables	Core Content	Recommended Presentation Format	Target Audience
Day 1 AM (Departure Day)	Structuring Original Notes	Organize all notes and photos into four categories	Feishu/Notion multi-column tables with tags and priority levels	Self
Day 1 PM	Competitor Pipeline Change Log	Competitor Data Extracts + Threat Level Markings	One Excel sheet with red/yellow/green markers + notes column	BD Lead
Day 2 AM	Technical Barrier Analysis Report	Answers to the three key questions for each barrier + action recommendations	2–3-page PPT/Word document, structure: Barrier → Impact → Action	CTO/VP of R&D
Day 2 PM	Talent/Partner List	HPP (High Priority Partners) Ranking + Engagement Strategy	One-page table with scores and contact templates	CTO/VP of HR
Day 2 PM (Final Draft)	WCP 2026 Strategic Briefing (Final Version)	Consolidation of the Above + Executive Summary	5–8-page PDF, with the Executive Summary at the beginning and details in the appendix	CEO/General Manager/Board of Directors

Day 2 (the day after returning): Consolidate findings into a strategic brief. Consolidate the analysis across the four dimensions into a 5–8-page strategic brief (Executive Brief) structured as follows: Page 1—Executive Summary: Summarize the three most important findings and recommendations from this WCP in no more than 200 words; Pages 2–3—Competitive Landscape: Based on the conclusions from Dimensions 1 and 2;Pages 4–5—Opportunities & Recommended Actions, based on the conclusions from Dimensions 3 and 4; Pages 6–8—Appendix, containing key raw data, photos of the posters, and a list of references.

 The value of this brief lies in the fact that it allows your boss or decision-makers to grasp the core insights you gained in Melbourne—which took you 5 days, over $5,000, and travel expenses—in just 15 minutes. This ability to “condense information” is far more valuable than a report that simply states, “I attended XX presentations.”In an era of information overload but cognitive scarcity, those who can help the company “streamline” are always irreplaceable members of the team.

 When it comes to managing information assets after the conference, there’s one practice that’s overlooked by the vast majority of attendees but offers an extremely high ROI: recording a 3–5-minute video summary on-site at WCP.Don’t get me wrong—this isn’t about turning you into a vlogger. Instead, after each day’s sessions, spend 15 minutes back at your hotel recording a short video on your phone highlighting your “Top 3 Insights” from that day. Speak in plain language—don’t read from a script—and simply share the three most impactful data points or presentations you encountered that day.This video serves three purposes: First, when you return to the office to report to your boss or team, you may have already forgotten the core takeaways from the conference details—but the video preserves that “sense of awe” from the moment. This emotional memory helps decision-makers understand the true weight of a data point far better than a cold Excel spreadsheet;Second, if you manage a global team across time zones, these videos serve as an asynchronous communication tool, allowing your team members—especially those who couldn’t attend—to grasp the key takeaways you’ve distilled over the course of the day in just five minutes;Third, if you’re a Business Development lead, these videos can serve as material to share your “impressions” of the WCP with external partners—posting a professional, insightful meeting summary video on LinkedIn is more effective for establishing your thought leadership in the industry than simply reposting an official press release.

 Finally, here are a few tried-and-true recommendations for dining and social spots in Melbourne.If you’re looking for lunch near the MCEC, I recommend avoiding the food court inside the convention center (high prices, long lines, and mediocre quality). Instead, take a 3-minute walk to The Boatbuilders Yard or BangPop, located next to the DLR (Docklands Light Rail) station at South Wharf. Lunch at these two spots costs around $20–35 AUD per person, and the quality is far superior to the convention center’s dining options.For dinner, if you’re looking to have an “informal yet meaningful” conversation with potential partners, I recommend Nobu at the Crown complex on South Bank (Japanese-Peruvian fusion cuisine, $100–150 AUD per person; book at least two weeks in advance) or Chin Chin on Flinders Lane (Southeast Asian fusion, $50–70 AUD per person; no reservations accepted; arrive around 5:30 pm to queue).If you’re on a budget but want a quality setting for conversation, Patricia Coffee Brewers in the CBD (Melbourne’s top-ranked specialty coffee shop—no Wi-Fi, but the best flat whites) is an excellent spot for informal one-on-one exchanges. Conversations at the founder/investor level often don’t happen in conference rooms; instead, they occur naturally in a quiet yet welcoming environment with great coffee.

 Action Recommendations: Before heading to Melbourne, create a “WCP 2026 Intelligence Gathering” template in Google Sheets or Feishu. The header row should include: Information Source (Poster ID/Oral Presentation ID/Personal Conversation), Company/Institution, Target/Technology, Indication, Clinical Stage, Key Data, Impact on Our Pipeline, Threat Level, and Action Recommendations.Then, during the conference, immediately after every presentation, every poster you view, and every conversation you have, take 30 seconds on your phone to fill in one row—this habit will save you at least three hours of “reminiscing” time during your structured review on Day 1.

 In addition to navigating the MCEC layout, Melbourne’s July weather is another factor attendees should prepare for in advance. July is winter in Melbourne, with daytime temperatures typically ranging from 6–14°C and nighttime lows potentially dropping to 2–5°C.Although the MCEC is heated, we recommend pairing your suit or business attire with a trench coat or light jacket that you can easily put on or take off during the conference. Melbourne’s winter is also known for its “four seasons in one day”—you may experience sunny skies, overcast skies, light rain, and gusty winds all within the same day.Essential items to bring: a compact umbrella (do not rely on the hotel’s limited supply of loaner umbrellas), a portable power bank (outlets inside the MCEC are in high demand, especially at charging stations near the venue entrance, where wait times during lunch can exceed 20 minutes), and a pair of comfortable walking shoes (the total walking distance at the MCEC can easily exceed 8–10 kilometers in a single day).

 On the social front, another “unwritten rule” of WCP is that the business value of the Gala Dinner and Welcome Reception far exceeds that of the daytime academic sessions. The WCP 2026 Gala Dinner is scheduled for the evening of July 15 at the Melbourne Museum, while the Welcome Reception will be held on the evening of July 13 in the foyer of the MCEC Plenary Hall.While business casual attire is typically acceptable for these events, if you are a business development lead or an investor, we strongly recommend dressing formally (suit and tie or equivalent formal attire). The reason is simple: in these social settings, your attire serves as a “nonverbal signal” that quickly signals your role.A well-tailored suit stands out in a crowd and signals to those approaching you that “I am an industry professional worth approaching”—when over 4,000 people are packed into a banquet hall and each person has only a few seconds to make a judgment, the value of this non-verbal signal is amplified.

 Here’s a practical tip: the Wi-Fi password and network quality for WCP 2026. Past WCP experiences have shown that the MCEC’s public Wi-Fi slows to a near-useless level when over 5,000 people are connected simultaneously (measured download speeds may drop below 1 Mbps).If you need to join company meetings remotely, send large files, or make video calls during the conference, we strongly recommend purchasing an Australian local SIM card in advance (a prepaid card from Telstra or Optus will suffice, costing $15–30 AUD for 7 days) and using a personal hotspot as a backup network.Telstra and Optus retail counters are located in the arrivals hall at Melbourne Airport (Tullamarine), so you can set up service immediately after landing. Another useful tip is to download an offline map of the MCEC in advance (Google Maps supports offline downloads for the Melbourne CBD area) to avoid getting lost in the convention center’s vast complex when there is no internet connection.

6.0 biological conference 2026 Melbourne: FAQ

 The following three questions are compiled based on Google’s “People Also Ask” search trends and the key features of WCP 2026, helping online followers quickly grasp the conference’s core highlights. The English version will be added during the subsequent translation and SEO optimization phase.

 Q1: What is the difference between WCP 2026 and ASCO 2026? Which one should I focus on?

 The two events have fundamentally different focuses. ASCO (the American Society of Clinical Oncology Annual Meeting) focuses on the release of clinical endpoints—data on OS, PFS, and ORR from Phase III trials are typically premiered at ASCO, and the primary attendees are clinical oncologists and pharmaceutical company medical affairs teams.WCP 2026, on the other hand, focuses on underlying pharmacological mechanisms—covering the entire spectrum from molecular structure to PK/PD modeling to translational medicine strategies. If your role is a business development lead, investor, or CMC/clinical pharmacology R&D professional, WCP provides in-depth insights into “why a drug works,” while ASCO offers validation data confirming “that a drug works.”The two conferences are scheduled back-to-back (ASCO in early June, WCP in July), so the optimal strategy is to attend both: gather the latest clinical data at ASCO, then bring the questions raised by that data to WCP to seek explanations at the mechanistic level.

 Another unique value of WCP lies in its quadrennial nature—some of the breakthroughs in basic pharmacology you see at WCP may not be updated at other conferences for the next 3–5 years. For decision-makers formulating medium- to long-term (3–5 year) R&D strategies, missing a single WCP session means missing a quarter-century’s worth of signals regarding industry trends in basic research.

 Q2: I am unable to attend WCP 2026 in person. How can I maximize my access to the conference’s key insights?

 Even if you cannot travel to Melbourne, the following methods can still help you “mine for gold” remotely:

 ① Utilize the “Virtual Access” feature on the official WCP 2026 app. The conference offers live streaming and on-demand replays for registered attendees who cannot attend in person (typically covering Plenary Lectures and selected Oral Sessions). The online registration fee is usually 40–50% of the on-site fee, making it a very cost-effective investment compared to travel expenses of $3,000+.

 ② Follow IUPHAR’s official social media accounts (Twitter/X @IUPHAR) and the conference hashtag #WCP2026. Based on past experience, attendees from academia and industry will share the most impactful data and insights in real time on Twitter/X—these “real-time highlights” serve as an efficient way to filter information.Follow key opinion leaders (KOLs) in the biopharmaceutical field (such as @Dr_ASCO_MD, @adamfeuerstein, etc.); their real-time tweets often contain more critical analysis than official press releases.

 ③ Subscribe to the author’s series of in-depth post-conference analyses.Within one week of WCP 2026 concluding, the author will publish an in-depth post-conference report based on firsthand data collected on-site and exclusive interviews—covering key data from each core session, behind-the-scenes business developments, and investment and R&D strategy recommendations for the next 6–12 months. If you’ve already subscribed to our newsletter, this report will be automatically sent to your inbox.

 Q3: Which “hidden gem” sessions at WCP 2026 are not to be missed?

 Based on an analysis of the current agenda, the following four sessions are the “must-attend” sessions with the highest information density at WCP 2026:

 ① Session 3A/4C (Molecular Pharmacology — GPCR Allosteric Modulation and Kinase Resistance): Covers the allosteric binding mechanisms of oral small-molecule GLP-1 agonists (see Chapter 2) and the latest preclinical data on fourth-generation EGFR/ALK/BTK allosteric inhibitors. If your company has any GPCR or kinase pipelines, these two sessions are not to be missed.

 ② Session 5B (Pharmacology of Drug Delivery Systems—ADC Linkers and PROTACs): Next-generation ADC linker designs (pH+enzyme dual-responsive, bioorthogonal click chemistry) and strategies to overcome the hook effect in PROTACs are all showcased here (see Chapter 3). BD executives are keeping a close eye on presentations from Daiichi Sankyo and the Koch Institute at MIT.

 ③ Session 11B/12D (CGT—CAR-T In Vivo Kinetics and Gene Editing Delivery): The CAR-T CRS prediction model from the UPenn June Lab, extrahepatic targeting data for SORT LNP, and tissue expansion of eVLP—this is the most valuable CGT technology segment at this year’s WCP (see Chapter 4).What you see here may well be the “prototype” of the next blockbuster CGT product to be approved by the FDA in three years.

 ④ Session 13 (Regulatory Science and MIDD): The latest policy directions from FDA and EMA officials regarding “Model-Based Drug Development (MIDD).” If you are preparing an IND or NDA submission, the changes in review criteria revealed in this session may directly impact your filing strategy (see Section 4.3).